JSP COVID-19 and the NUMBERS

s.18(b)
s.68.1

March 27, 2020

Some Friday thoughts on our formidable COVID-19 coverage.

Thank you !

Paul Hambleton

Director of Journalistic Standards

CBC News

Language note: Convoy protests: avoid 'so-called'

s.18(b)
s.68.1

Oct. 24, 2022

Hi everyone,

[redacted]

Thanks,

George and Blair

George Achi, Director of Journalistic Standards

Blair Shewchuk, Senior Standards Editor

s.18(b)
s.68.1

JSP and Social Media

March 30, 2020

Paul Hambleton

Director of Journalistic Standards

CBC News

Is this page incorrect? Incomplete?

A0078906_3-000003

JSP COVID-19 reflections

s.18(b)
s.68.1

April 17, 2020

I would like to pass on some observations from the JSP desk on COVID-19 issues I've seen come up recently.



So much good work being done - thanks for keeping this stuff in mind!

Paul Hambleton

Director of Journalistic Standards

C ⓘ News

Is this page incorrect? Incomplete?

Some JSP thoughts

s.18(b)
s.68.1

Aug.25, 2020

Hi everyone;

Impartiality, balance and fairness are always top of mind and I thought I'd raise a couple of familiar themes that surfaced through some of the audience feedback I got over the past couple of months.

Thanks for your vigilance on these things

Paul

Paul Hambleton

Director of Journalistic Standards

CBC News

JSP notes - COVID-19

s.18(b)
s.68.1

Sep. 9, 2020

Hey there

Two things to bear in mind that have surfaced recently.

Thanks for your attention to these important matters !

Paul

Paul Hambleton

Director of Journalistic Standards

CBC News

More JSP thoughts and considerations

s.18(b)
s.68.1

Oct. 5, 2020

Here are some observations from me about issues that surfaced recently: (Long read alert)

PRECISION



Thank you for keeping all this stuff top of mind.

Paul

Paul Hambleton

Director of Journalistic Standards

Is this page incorrect? Incomplete?

s.18(b)

s.68.1

Friday JSP thoughts - election

Aug. 20, 2021

Thank you for your attention to these important issues !

Paul

Paul Hambleton

Director of Journalistic Standards

CBC News

News Editor's Blog · Editor's Note

An update on local services and all the ways to access COVID-19 information on CBC News

Everything from a new email destination for your questions to a dedicated page tracking coronavirus cases

Brodie Fenlon · CBC News · Posted: Mar 25, 2020 5:51 PM EDT | Last Updated: March 29, 2020

CBC News is bringing you all the latest information on the COVID-19 pandemic in all platforms: TV, radio, online and social media. (Michael Wilson/CBC)

comments

We are all involved in a remarkable story.

As we move forward into the next few weeks and what most experts agree will be the most perilous part of the COVID-19 pandemic in Canada, we must not lose sight of the human face of this crisis.

Canadians are ill and some have died; we will tell their stories.

Canadians are fighting; we will showcase the first responders and health care workers working flat-out to save lives and the challenges they face.

Canadians are worrying; we will get answers, aggregate the best advice and hold our officials to account.

Canadians are helping; we will find the stories of hope and civic generosity that bring communities together.

We are seeing millions of Canadians turn to CBC News daily on TV, radio, digital and social media. Every word we publish, post and broadcast matters in the face of this voracious appetite for trusted news, context and the latest developments. We cannot afford a misstep, and I'm grateful for the care and diligence that our staff bring to our reporting every day.

This is what public service journalism is all about.

Resources to answer your questions on COVID-19

Some quick highlights from the past two weeks:

- To manage the thousands of questions we're getting from Canadians, we have set up a new email destination and will endeavour to answer as many as possible on all of our programs and platforms. Write to **COVID@cbc.ca**

- We launched a COVID-19 fact checking unit to expose falsehoods and disinformation around the global pandemic. See some of their early work **here** and **here**.

- We made CBC News Network (NN) freely available on cable and digital to all Canadians, here and abroad.

- We launched a COVID-19 newsletter. It's already at 48,000 subscribers, our fastest-growing newsletter. A remarkable 70 per cent of users open this daily email. Sign up **here**.

- On CBC Radio One, we have extended the *Current* with Matt Galloway until noon in most time zones in order to provide you with the latest information and updates.

- Our **coronavirus tracker** is live. It will give you the latest data on the number of confirmed cases of COVID-19 as we know them, here and around the world.

- Our CBC News app will launch an update soon that will contain a COVID-19 guide to help our local audiences access resources, local stories and key video about their community.

- We've compiled local resources and updates for communities across Canada **here**.

- We have partnered with Canada's private broadcasters to pool video coverage of official press briefings across the country in order to space out the number of crews present at any one event.

WATCH | One of the many videos you can find on CBC News to help you stay safe during the COVID-19 pandemic:

Why gloves won't do much to protect you from COVID-19

3 years ago | 1:54

Dr. Samir Gupta explains why most people are better off washing their hands with soap and water than wearing gloves for protection against COVID-19.

Slowly ramping up local programming

As I noted in an earlier blog, we temporarily paused our local 6 p.m. newscasts last week and moved quickly to shore up our ability to offer local and national programming on CBC TV and CBC News Network.

That decision was the result of us broadcasting more live events, press conferences and daily video than ever in the history of CBC News, which caused a logjam at our centralized resource desk in Toronto at the exact same time staffing levels there had dropped on account of COVID-19.

We are broadcasting more live events, press conferences and daily video than ever before, such as this COVID-19 briefing Tuesday by B.C. health officer Dr. Bonnie Henry. (Michael McArthur/CBC)

We also wanted to get ahead of the staffing crunch we anticipate in the next several weeks as more of our staff in newsrooms across the country are forced to self-isolate, work from home and potentially fall ill.

We are working in new ways with far fewer people available to do the resource-intensive work of television production.

We promised to assess the situation daily and bring the supper hour newscasts back as soon as possible — a commitment we took seriously. Since last week, we've stabilized demands on our resources desk and can now channel some of our social media live streams through new software. We also created redundant systems for our television control rooms and resource work areas.

CBC News has compiled a wealth of resources on closures and other essential information you need to know to get through this public heath emergency. (Ben Nelms/CBC)

While it's certainly not business as usual in these times, we will begin a gradual, staggered return to local news on CBC TV at 6 p.m. We started today with the return of a half-hour newscast in Newfoundland and Labrador. Beginning tomorrow, we will broadcast a half-hour of *Compass* from P.E.I. and a half-hour Atlantic newscast from Halifax covering Nova Scotia and New Brunswick.

We will take it one day at a time, continually adding back where we can while ensuring that nothing jeopardizes the essential services we intend to provide Canadians through to the very end of this crisis.

It's important to remember that our commitment to local journalism on radio, TV, digital and social remains unchanged.

As always, thank you for your patience and continued support of CBC News at this unprecedented time.

WATCH | Part of our job is sharing stories of how Canadians are coping and helping each other through this crisis:

All alone, together: Helping each other during COVID-19

3 years ago | 3:04

How Canadians across the country are helping each other through the COVID-19 pandemic.

CBC's Journalistic Standards and Practices | *About CBC News*

Corrections and clarifications | *Submit a news tip* | *Report error*

CBC NEWSLETTERS

A variety of newsletters you'll love, delivered straight to you.

Email address:

Enter your email address

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1329 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

361 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

324 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

280 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

250 reading now

RECOMMENDED FOR YOU

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

Emily Chung

News - Science

C.B.S. family feel young son's daycare dismissal is discriminatory

Heather Gillis

News - Canada - Nfld. & Labrador



U.S. Marines without confirmed leader due to Republican senator's abortion opposition

News - World



Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics

3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

News Editor's Blog · Editor's Note

A peek behind the curtain: How CBC staff are covering the pandemic

Journalists and technicians have had to find new ways of covering and broadcasting the news during COVID-19

Brodie Fenlon · CBC News · Posted: Apr 03, 2020 9:21 PM EDT | Last Updated: April 6, 2020

Metro Morning host David Common puts out a call for Work From Home photos in Toronto. (David Common)

Hide caption 1 of 22

comments

I'd like to take a moment to share how our journalists across the country are working in new and innovative ways to bring you the latest on the COVID-19 pandemic.

But first, I want to acknowledge those working in essential services: from first responders, personal care and support workers, nursing home and shelter staff to everyone on the front lines of Canada's public health and health care systems.

You are being tested like never before. We will continue to tell your stories and document the challenges you face as the pandemic surges.

Let me also acknowledge the uncertainty so many Canadian workers face as layoffs, furloughs and workplace shutdowns mount.

We have documented the economic fallout, the impact on families struggling with rent and mortgages, how Canadians can apply for emergency benefits and what federal and provincial governments are doing for businesses.

Ottawa's Omar Dabaghi-Pacheo puts a new coronavirus-era spin on the typical media 'streeter' as he and his interview comply with physical distancing guidelines. (Omar Dabaghi-Pacheco)

We will not let up on this critical element of the COVID-19 story.

We would never compare to front-line health care services what we do at CBC. But we believe strongly that we are an essential service of another sort; that we play a critical role in conveying trusted, credible information in this time of crisis while also holding authorities to account for the life-changing decisions they make.

A CBC/Radio-Canada vehicle gets a scrub down in the garage of Maison de Radio-Canada in Montreal. (CBC/Radio-Canada)

That sense of mission is shared widely by the many other reputable news organizations in Canada and around the world doing some exemplary journalism on TV, radio, digital and in print.

- INTERACTIVE **Coronavirus tracker: The cases, hospitalizations and vaccinations in your area**
- UPDATED **Masks and COVID-19: When, how and why you'd wear them**

Journalism, especially broadcast journalism, is not easy to do when the majority of staff are at home and newsgathering is constrained by physical distancing and risk mitigation.

Journalist Julia Caron, based in Quebec City, is working from home during the pandemic and like many Canadians, is juggling family and work responsibilities. (Julia Caron)

Yet our staff are pulling off daily feats of invention and ingenuity to bring you the journalism you expect.

For example:

- Newsrooms across the country are largely empty, with video conferencing the key connection point for staff all day long.

- Many of our radio hosts are broadcasting live-to-air from home (see some of them in action in the photo gallery above).

- Staff are also producing our biggest TV programs, including *The National* and CBC News Network, from home, with only a core group left in our buildings.

A0078907_14-000023

WATCH | Lineup producer Meg Banks gives viewers a tour of her home studio, which she uses to connect with the control room inside the CBC building and bring *The National* to air:

How we make The National from home

3 years ago | 1:06

Producer Meg Banks shows off the makeshift control room that she has put together at her Toronto home, from which she brings The National to air every night during the COVID-19 lockdown.

- Our News Network team adapted an app that essentially turns a smartphone into an intercom so they can speak to each other and to hosts from home and the control room in real time as they program an extraordinary amount of live, breaking news.

- Nearly all appearances by guests, panellists and interview subjects are done by video conference.

- When the story warrants newsgathering in the field, reporters and camera crews are largely sticking to outdoor shoots, with a rigorous process built around distancing our microphones and disinfecting gear afterward.

Interviews have gotten more challenging in the time of COVID-19. Here, Tina Lovgreen keeps her distance from her interview subject in Vancouver. (CBC)

Aesthetically, the end product is not always perfect: audio gets clipped; the sound can be flawed; video is sometimes pixelated or freezes or drops altogether; transitions can be bumpy.

- EDITOR'S NOTE **Why CBC News is making changes to local programming during the COVID-19 crisis**
- **CBC temporarily replaces local evening TV news amid coronavirus pandemic**

Thank you for your patience through it all.

Rest assured the rigour of our journalism and the quality of the information we provide Canadians is as rock solid as ever.

Working from home does have its advantages: no shoes and a cosy quilt for Janice Goudie, host of Labrador Morning. (Janice Goudie)

CBC's Journalistic Standards and Practices | *About CBC News*

Corrections and clarifications | *Submit a news tip* | *Report error*

CBC NEWSLETTERS

A variety of newsletters you'll love, delivered straight to you.

Email address:

Enter your email address

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1329 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

361 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

324 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

280 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

250 reading now

RECOMMENDED FOR YOU

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

Emily Chung

News - Science

C.B.S. family feel young son's daycare dismissal is discriminatory

Heather Gillis

News - Canada - Nfld. & Labrador



U.S. Marines without confirmed leader due to Republican senator's abortion opposition

News - World

Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics



3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

News Editor's Blog · Editor's Note

Managing risk to get closer to the COVID-19 story

Many of our journalists are working from home, but some are still reporting from the front lines. Here's how.

Brodie Fenlon · CBC News · Posted: Apr 13, 2020 11:54 AM EDT | Last Updated: April 13, 2020

The National host Adrienne Arsenault conducts an interview at Toronto's Humber River Hospital, using some of the safety techniques CBC News has implemented during the COVID-19 pandemic. (Jared Thomas/CBC)

At CBC News, we are doing things differently — much differently — as we work to bring you the latest information about the coronavirus pandemic, investigate the important questions that need answering, and take you to the story we are all trying to properly comprehend.

Most of our staff at CBC News are now working remotely; most of our interviews now are conducted through video conference, and we have put in place strict protocols for any journalist who needs to go out in public — both for their safety and for the safety of the people to whom we talk.

At the core of the COVID-19 story, though, are the profound disruptions to society, and the drastic actions taken by governments and officials trying to flatten the curve. The beating heart of this strange new normal is found at the front lines, where those workers who confront this virus daily must go to help keep us safe: the doctors and nurses, the emergency room, first responders, nursing home employees and the staff of other facilities that cater to vulnerable populations.

In these situations, our job as journalists is to get to those front lines, to bear witness so you can see and hear what is really going on. We do this carefully, tasking some of our most experienced reporters to reveal the challenging reality on the ground.

Correspondent Susan Ormiston gets ready for a shoot in New York City, setting up an extended microphone. (Paul-André St-Onge Fleurent/CBC)

For instance, Washington correspondent Susan Ormiston and videographer Paul-André St-Onge Fleurent (with offsite producer support from Sylvia Thomson) took us to New York City to investigate how one of the world's most dynamic and iconic cities has become a "ground zero" in the United States yet again, coping with daily death counts in the hundreds, surpassing the overall number of those killed in the 9/11 attacks.

Watch Susan's story below and read her piece today on CBCNews.ca.

Inside the fight against COVID-19

3 years ago | 2:01

CBC's Adrienne Arsenault goes inside a Toronto hospital to see the fight against COVID-19

And *The National* host Adrienne Arsenault and video producer Jared Thomas (with offsite producer support from Jennifer Barr) embedded this week with a team of doctors and nurses at Humber River Hospital in Toronto for a rare opportunity to see firsthand what's happening inside. The hospital was designed just after the SARS outbreak of 2002-2003 and built around best practices for managing pandemic and hazmat situations.



How do the front-line staff do it? What precautions do they take? What personal risks are they taking? What can you expect if you have to be admitted? You can watch Adrienne's stories tonight and tomorrow on *The National*. Read more here.

- **CBC goes inside Toronto hospital to show the fight against COVID-19**
- EDITOR'S NOTE **A peek behind the curtain: How CBC staff are covering the pandemic**

There is always some risk in pursuing these types of stories, but we have plenty of experience deploying journalists to more dangerous locales. For COVID-19 assignments, like the two

mentioned above, we deploy with the same care and preparation we take on high-risk assignments. This includes:

- Limiting the size of the crew to two people.
- Taking only as long as we need in the field.
- Reducing gear and eliminating elaborate interview setups.
- Carrying what we need in backpacks so nothing is put down.
- Travelling in one vehicle — one person up front, the other in the back — and the vehicle is cleaned meticulously each day.
- Shooting subjects outdoors from a safe distance with extended microphones.
- Using sanitizer after any possible exposure, such as filling up our vehicles with gas.
- Using masks in all situations where distance cannot be strictly controlled. For Adrienne's story, we did not take any PPE from hospital staff.
- Thoroughly wiping down regularly the hard surfaces we use.
- Cleaning and sanitizing our equipment at the end of the shoot.

Adrienne Arsenault conducts an interview with a patient at Toronto's Humber River Hospital, maintaining a safe distance for both parties. (Jared Thomas/CBC)

Guiding these types of deployments is the principle of public interest. We will always act as your eyes and ears on the ground when it matters most.

- INTERACTIVE **Coronavirus tracker: The cases, hospitalizations and vaccinations in your area**
- UPDATED **Masks and COVID-19: When, how and why you'd wear them**

P.S.: Please join us this Wednesday, April 15, at 7 p.m. ET on all CBC platforms for a virtual town hall to mark a month since COVID-19 changed life for Canadians with distancing and travel restrictions. The CBC News special will be hosted by Heather Hiscox and Ian Hanomansing, with additional hosting on CBC Radio One by Piya Chattopadhyay.

COVID-19 a test of New York's strength

3 years ago | 2:55

New York City's streets are largely empty as it continues to grapple with record death tolls from COVID-19. CBC's Susan Ormiston looks at how the pandemic is testing the strength of the city and its residents.

A0078907_26-000035

CBC NEWSLETTERS

A variety of newsletters you'll love, delivered straight to you.

Email address:

Enter your email address

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1194 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

343 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

319 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

263 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

255 reading now

RECOMMENDED FOR YOU

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

C.B.S. family feel young son's daycare dismissal is discriminatory



U.S. Marines without confirmed leader due to

Emily Chung

News - Science

Heather Gillis

News - Canada - Nfld. & Labrador

Republican senator's abortion opposition

News - World

Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics



3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

News Editor's Blog · Editor's Note

Why we can't tell you the full COVID-19 story

CBC project Lives Remembered is an attempt to honour those who died and understand the pandemic

Brodie Fenlon · CBC News · Posted: Apr 30, 2020 4:00 AM EDT | Last Updated: April 30, 2020

Garry Monckton 'remarkable in so many ways' | COVID-19 Lives Remembered

3 years ago | 1:58

Samantha Monckton lost her dad, Garry, to COVID-19 on April 2.

comments

Today, we are launching Lives Remembered, a CBC News commitment to honour and also understand more about the Canadians who have lost their lives to the novel coronavirus pandemic.

Canada has tens of thousands of cases of COVID-19, the illness caused by the virus, and as of this writing, more than 3,000 deaths, a number that will, tragically, grow. As a national news organization with a public service mandate, we want to pay homage to those we have lost by telling their stories in words and videos.

But not only that.

As well as honouring the memory of people who have fallen victim to COVID-19, it is important to know who the most vulnerable are and why. We believe it's our duty to uncover and help Canadians better understand how this deadly virus moves among us.

An incomplete picture

Unlike many other countries, Canada has an incomplete picture of the toll of COVID-19. We know long-term care and seniors homes are hit hard, but those homes are regulated provincially, with no national database that can tell us more about this tragic story.

Data in other countries has revealed deep inequities based on race, suggesting a greater burden of illness and death among certain minority groups.

Here in Canada, we don't know.

- LIVES REMEMBERED **What we learned about the first 1,000 COVID-19 deaths in Canada**
- INTERACTIVE **Coronavirus tracker: The cases, hospitalizations and vaccinations in your area**

Are low-income workers at greater risk of exposure? Are racialized and Indigenous Canadians disproportionately affected? Which occupations are most likely to put workers at risk? Does where you live make you more susceptible?

The answers are simply not available — or protected for privacy reasons — in the limited data we get from authorities.

Understanding more about this virus is key to managing it.

WATCH | 'He was magnetic': Jennifer Auger recalls her husband, Shawn, who died of COVID-19:

Shawn Auger made you feel like 'you belonged somewhere'

3 years ago | 1:39

Jennifer Auger lost her husband, Shawn, to COVID-19 on March 30.

A database of those lost

With Lives Remembered, we are setting out to gather as much information about the people who have died as possible, to learn who is being disproportionately affected and to help us all understand how to deal with this pandemic in the months ahead.

This is why we have dedicated a talented team of journalists to find some answers, beginning with our story today on the first 1,000 COVID-19 deaths in Canada. Over the past month, the team has built a deep database of everything we can gather on not just these but all Canadians whose deaths have been linked to COVID-19.

- INTERACTIVE **Find the COVID-19 benefits and programs relevant to you**
- **'A race against the disease': Canadian researchers part of global effort to develop COVID-19 vaccine**

We have reached into your communities to learn more about the lives of the people who have died.

This is unlike any mass tragedy we've lived through. We knew the who, what, when, where of the victims of the 9/11 terror attacks within days. We knew within hours the names of the people killed when Flight 752 was shot down earlier this year over Tehran.

With this pandemic, governments and health authorities in many areas of our country are not releasing basic demographic data on factors such as age and race, or even when Canadians died or where.

WATCH | Isabelle Mikhail's cooking was 'epic' and brought people together, her daughter May told CBC:

Isabelle Mikhail 'gathered family around the table' | COVID-19 Lives Remembered

3 years ago | 1:50

May Mikhail lost her mother, Isabelle, to COVID-19 on March 18.

A deeply personal story

As we endeavour to report on the people behind these impersonal numbers, we sometimes encounter shame and fear, which has also made it difficult to tell the full story of lives lost.

In a sense, these Canadians are being made invisible. At CBC News, we want to bring some recognition if possible.

We know that for many Canadians this is a deeply personal story. Many of you have already reached out to tell us about a loved one, in moving and profound ways. You have told us you wish to honour your loved ones, and also of your desire to contribute to a greater understanding of the problem.

- INTERACTIVE **Are Canada's efforts to flatten the curve working?**
- VIDEO **'This too shall pass': Pandemic pep talks from Canadian WW II veterans**

And you want to be sure that the people who succumb to COVID-19 are more than a statistic, which is why an important part of Lives Remembered will be to tell those stories in words and pictures in the weeks and months ahead.

If you would like to share the story of a loved one who has died of COVID-19, email us at COVID@cbc.ca.

Finally, privacy is important to us. This email is being monitored by a small team of CBC journalists who are endeavouring to get back to as many people as possible.

Whether you wish to remain anonymous or tell the story of a loved one lost publicly, we would like to hear from you.

CBC's Journalistic Standards and Practices | *About CBC News*

Corrections and clarifications | *Submit a news tip* | *Report error*

CBC NEWSLETTERS

A variety of newsletters you'll love, delivered straight to you.

Email address:

Enter your email address

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1194 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

343 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

319 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

263 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

255 reading now

RECOMMENDED FOR YOU

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

Emily Chung

News - Science

C.B.S. family feel young son's daycare dismissal is discriminatory

Heather Gillis

News - Canada - Nfld. & Labrador



U.S. Marines without confirmed leader due to Republican senator's abortion opposition

News - World

Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics



3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

News Editor's Blog · Editor's Note

Canada not immune to the virus of COVID-19 conspiracies

Credible journalism, fact checks by reputable news organizations offer a 'cure' to the misinformation epidemic

Brodie Fenlon · CBC News · Posted: May 25, 2020 3:24 PM EDT | Last Updated: May 25, 2020



A video that has gone viral with the claim that the coronavirus was caused by 5G technology has been debunked by virologists. CBC News and other credible news organizations have devoted resources to fact-checking COVID-19 claims in an effort to combat misinformation. (Jeff Yates/CBC)

Like the coronavirus, conspiracy theories and misinformation about COVID-19 are contagious and can spread easily among Canadians.

- Is hydroxychloroquine an effective treatment for those infected?
- Was the coronavirus genetically engineered in a lab as a biological weapon?
- Does regularly rinsing your nose with a saline solution protect you from the coronavirus?

False, unproven and not true, respectively.

Yet recent research suggests Canadians are exposed to a high level of bad information about COVID-19, and many are vulnerable to what some have described as "a pandemic of misinformation" or an "infodemic."

Carleton University's School of Journalism and Communication released a survey last week that showed nearly half of Canadians, 46 per cent, believed at least one of four COVID-19 conspiracy theories. Similar research at the University of Sherbrooke in Quebec indicated one in 10 Canadians believes a conspiracy theory.

WATCH | Experts warn about products claiming to cure, prevent coronavirus:



Experts warn about products claiming to cure, prevent coronavirus

3 years ago | 1:54

From standing on your head, to drinking a special herbal tea -- experts are warning Canadians against falling for phony cures for COVID-19.

Both studies found that young people were more likely to believe in conspiracy theories and false news. That's not surprising considering that disinformation is most prevalent — and spreads most easily — on social media, which is a primary source of news for younger Canadians.

But all ages are susceptible.

"Everyone has fallen prey at some point to misinformation on social media," Sarah Everts, an associate professor and co-researcher on the Carleton study, said on the university's website. "Anyone who thinks that it's easy to distinguish conspiracy theories and misinformation is at high risk of being fooled."

Trust in news at record high

While some of the major social media and search platforms are taking measures to limit and reduce the amount of misinformation on their feeds, it is difficult to control the internet. CBC News has found that even discredited stories and bogus claims — such as *Plandemic*, a 26-

minute documentary-style video full of false and misleading claims about COVID-19 — continue to resurface on alternative sites and platforms.

It's all the more reason why reputable news organizations must devote resources to fact-checking COVID-19 claims.

The good news is that a number of serious media outlets in Canada have done just that by dedicating journalists to this important work.

The better news is that public trust in those traditional news organizations soared to record highs in Canada as the pandemic took hold, according to a new special edition of the "Trust Barometer" report by marketing firm Edelman Canada.

- **Canadians have lost more than $1.2 million to COVID-19 scams**

At CBC News, we launched a COVID-19 disinformation unit to fact-check viral COVID-19 claims on social media and other platforms. The goal is to hold platforms to account for the spread of bad information and unverified claims; to provide accurate takes on that information from verified experts; and to try to help Canadians navigate the minefield of false and misleading information. Find links to some of the team's recent work below.

(CBC's French-language service Radio-Canada has a similar unit, Décrypteurs.)

WATCH | CBC's Marketplace debunks COVID-19 immunity scams:



Debunking COVID-19 immunity scams

3 years ago | 5:27

Misinformation about so-called miracle cures for COVID-19 are spreading online. Can you really buy your way to a better immune system? We ask an expert: UBC professor Bernie Garrett, who studies deception in healthcare, including alternative medicine.

Meanwhile, a team of journalists attached to our "Ask CBC News" (COVID@cbc.ca) project has received more than 41,000 questions from our audience on the pandemic, and some of their work addresses misinformation. The team has directly responded to more than 2,200 people, and many user questions have been put to experts on the air or published in one of our more than 40 FAQ articles. These pieces are consistently among the most-read articles on our website.

We recently launched our "Students Ask CBC News" initiative with Curio.ca. Every Tuesday night, CBC News Network produces a live segment dedicated to questions from high school students and expert answers.

And as a member of the Trusted News Initiative, CBC/Radio-Canada joined an industry collaboration of major media and technology companies in March to rapidly identify and stop the spread of harmful coronavirus disinformation.

We view this work as essential public service and are fully committed to it. For as long as there's an "infodemic," CBC News aims to be part of the cure.

Some recent fact checks by our COVID-19 disinformation unit:

No, the new coronavirus wasn't created in a lab, scientists say

No, you can't make an N95 mask out of a bra

Viral video claiming 5G caused pandemic easily debunked

Mushrooms, oregano oil and masks targeted in crackdown on misleading COVID-19 ads

No, someone wasn't fined for sharing a car in Yellowknife during the pandemic

Chiropractors told to remove posts claiming their methods boost immune system and prevent COVID-19

CBC's Journalistic Standards and Practices | *About CBC News*

Corrections and clarifications | *Submit a news tip* | *Report error*

CBC NEWSLETTERS

A variety of newsletters you'll love, delivered straight to you.

Email address:

Enter your email address

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1194 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

343 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

319 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

263 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

255 reading now

RECOMMENDED FOR YOU

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

Emily Chung

News - Science

C.B.S. family feel young son's daycare dismissal is discriminatory

Heather Gillis

News - Canada - Nfld. & Labrador



U.S. Marines without confirmed leader due to Republican senator's abortion opposition

News - World

Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics



3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

News Editor's Blog · Editor's Note

How CBC covered a year of unprecedented news stories

In the unrelenting news cycle of 2020, the extraordinary became routine

Brodie Fenlon · CBC News · Posted: Dec 23, 2020 4:00 AM EST | Last Updated: December 23, 2020

Delilah Kamuhanda, an organizer with Black Lives Matter YXE, spoke with volunteers ahead of a Black Lives Matter demonstration in Saskatoon in June. The killing of George Floyd sparked global protests, calls to defund the police and a reckoning over anti-Black racism and systemic discrimination that reverberates to this day. (Morgan Modjeski/CBC)

comments

We use this editor's blog to explain our journalism and what's happening at CBC News. You can find more blogs here.

For journalists, it is almost impossible to describe the events of this remarkable year without sounding hyperbolic. Few of us have worked through such an unrelenting news cycle, where each story seems to dwarf the one that came before and where the unprecedented has become the routine.

For me, the bookends of 2020 were stories of tragedy and hope.

A year of unprecedented news stories

3 years ago | 3:17

From the downing of Ukraine International Airlines Flight PS752 in Iran to the deadly mass shooting in Nova Scotia and the life-altering impacts of the coronavirus pandemic, CBC journalists covered extraordinary events and developments in 2020.

The new year was just days old when Iran's Revolutionary Guard Corps shot down Ukraine International Airlines Flight PS752, shortly after it took off from Tehran. The attack with surface-to-air missiles on Jan. 8 killed all 176 people on board, including 138 people with ties to Canada. The tragic, senseless loss of life touched Canadians deeply as family photos of the dead filled our screens.

It would be, I thought at the time, one of Canada's biggest stories of the year. It turned out to be one of many.

Nearly 12 months later, the COVID-19 pandemic's second wave rages in much of Canada, and many tough months lie ahead. But there was an undeniable feeling of hope as "V Day" arrived on Dec. 14, and Canada's first doses of the Pfizer-BioNTech vaccine were administered in Quebec and Ontario.

In between these bookends were months of extraordinary events and developments in a year unlike any other at CBC News, including:

- The shutdown of large parts of the Canadian economy and a record-surge of government spending and massive debt to try to contain a virus that has infected more than 520,000 and killed more than 14,400 of us in Canada.

- The worst **mass shooting in Canada's recent history** after a gunman masquerading as an RCMP officer killed 22 people in several communities in rural Nova Scotia over 13 devastating hours in April.

- The killing of **George Floyd in Minneapolis**, which sparked global protests, calls to defund the police and a reckoning over anti-Black racism and systemic discrimination that reverberates to this day.

- Three provincial elections, a federal confidence vote and two national leadership races that resulted in **Erin O'Toole** taking the helm of the Conservative Party and Canada's Official Opposition while Green Party Leader **Annamie Paul** made history as Canada's first Black leader of a federal party. And we covered the **state funeral** of former prime minister John Turner.

- The **crash of a CH-148 Cyclone helicopter** into the Ionian Sea off the coast of Italy in April that killed six members of the Canadian military — four air crew and two sailors. The following month, a member of the Canadian Forces **Snowbirds team was killed** and a pilot injured after ejecting from their plane, halting a cross-Canada tour meant to lift the spirits of Canadians and salute front-line workers during the pandemic.

- The relatives of one of the "two Michaels," breaking their silence in **an exclusive interview** with the CBC's Adrienne Arsenault to discuss China's ongoing detention of

Michael Kovrig and Michael Spavor. A week after that interview aired, China passed, in secret, a sweeping new security law for Hong Kong, giving Beijing broad powers to **crack down on protest** and other activities deemed secessionist or subversive in the former British colony. **Arrests began within a day** of the new law.

- Joe Biden's defeat of Donald Trump in a bitterly polarizing U.S. presidential election that saw many firsts: amid record turnout, the contenders also each set records for the **most votes cast for a presidential candidate** (Biden at more than 81 million and Trump at more than 74 million); Biden's running mate, Kamala Harris, became the first woman and first woman of colour to win the vice-presidency; and Trump became the **first defeated president in a century and a half** to cling to power after losing the electoral college vote, refusing to concede or accept the results of a vote he **baselessly claimed was rigged**.

Sharing stories of loss, perseverance

The demands on our staff to tell these stories and so many others — a heavy lift in the best of times — were particularly intense as we adjusted to physical distancing, personal safety equipment and the need to work from home. Kitchen tables became edit suites; living rooms became control rooms; closets became recording studios.

We mounted more than 60 news specials on Radio, TV and CBC News Network — a record. We produced and packaged millions of words and hundreds of images. Some of us continued to venture into our quiet, hollowed-out newsrooms to put shows to air.

In the field, we learned how to interview at a safe distance, how to clean vehicles and gear after every assignment. Some of our staff were verbally harassed on the streets for doing their jobs, a worrying sign that the polarization and delegitimization of journalism, so fervently stoked by some camps in the U.S., has taken root in this country.

We persevered.

We are proud of our work.

And still, we are mindful of those who have given so much more of themselves on the front lines of this pandemic: nurses, doctors, paramedics, public health staff, personal support workers and long-term care employees. We think of those who have died and their loved ones who opened up to us. We thank those who recovered and found the courage to share their stories in the hope of enlightening others about the realities of this pernicious disease.

It's a privilege to tell these stories, and we'll continue to do so.

- **WATCH: A year of unprecedented stories at CBC News**

As Arsenault says in the video above, "When this ends, and it will end, we'll still be here, with you."

CBC's Journalistic Standards and Practices | *About CBC News*

Corrections and clarifications | *Submit a news tip* | *Report error*

Popular Now in News

1 NEW

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

1194 reading now

2 **C.B.S. family feel young son's daycare dismissal is discriminatory**

343 reading now

3 **Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine**

319 reading now

4 **U.S. Marines without confirmed leader due to Republican senator's abortion opposition**

263 reading now

5 **Toronto landlord launches $1.6M lawsuit after city gave stranger approval to rent her condo on Airbnb**

255 reading now

RECOMMENDED FOR YOU



A0078907_48-000057

Canada's Crawford Lake chosen as 'golden spike' to mark proposed new epoch

Emily Chung

News - Science

C.B.S. family feel young son's daycare dismissal is discriminatory

Heather Gillis

News - Canada - Nfld. & Labrador

U.S. Marines without confirmed leader due to Republican senator's abortion opposition

News - World

Fallout from U.S. cluster munitions decision strains NATO unity over Ukraine

Murray Brewster

News - Politics



3 arrested after Moncton woman stabbed to death

Shane Magee

News - Canada - New Brunswick

©2023 CBC/Radio-Canada. All rights reserved.

Visitez Radio-Canada.ca

From: computer@torbmepplinw01.local
To: red@cbc.ca
CC:
Subject: [Alert Desk - Flash] CBC-COVID-CDA-WILL-GET-VACCINE-IN-DECEMBER

Livelink ID: [redacted]
Sent Date: 2020-12-7 11:16 EST
Received Date: 2020-12-7 11:16 EST

s.16(2)(c)
s.18(b)
s.68.1

(Sourcing approved by Chris Carter)

Online file being updated here: https://www.cbc.ca/news/politics/trudeau-announcement-otoole-vaccine-motion-1.5830938

By David Cochrane

[redacted]

Priority FLASH

s.16(2)(c)
s.18(b)
s.68.1

From: computer@torbmepplinw01.local
To: red@cbc.ca
CC:
Subject: [Alert Desk - Flash] CBC-COVID-FED-TRAVEL-REPORTABLE

Livelink ID: [redacted]
Sent Date: 2022-9-20 6:26 EDT
Received Date: 2022-9-20 18:26 EDT

Flagged by Philip Ling

Re: Reportable on travel requirements

UPDATED – FOR REPORTING – sourcing approved by Chris Carter:

[redacted]

Sourcing approved by Chris Carter:

[redacted]

--
Philip Ling | Senior Producer, CBC News Parliamentary Bureau

Priority FLASH

--
You received this message because you are subscribed to the Google Groups "Red" group.
To unsubscribe from this group and stop receiving emails from it, send an email to Red+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

From:	computer@torbmepplinw01.local	**Livelink ID:**	
To:	red@cbc.ca	**Sent Date:**	2020-12-7 11:19 EST
CC:		**Received Date:**	2020-12-7 11:19 EST
Subject:	[Alert Desk - Flash] CBC-COVID-POLS-NOTE-WORDING-VACCINE		

Please note wording on vaccine breaking story:

(From Chris Carter)
And please note wording: this is about "taking delivery of doses" or "vaccine delivery" etc. -- it is NOT about "approval" -- that will come from the regulator independently ...

Priority FLASH

From: computer@torbmepplinw01.local
To: red@cbc.ca
CC:
Subject: [Alert Desk - Flash] CBC-COVID-VACCINE-PROOF-ROLLOUT

Livelink ID: [redacted]
Sent Date: 2021-6-17 6:36 EDT
Received Date: 2021-6-17 18:36 EDT

via Philip Ling **s.16(2)(c)**

NEW: "Proof of vaccine credentials" to roll out early next month **s.18(b)**

Sourcing approved by Chris Carter. **s.68.1**

From Ashley Burke:

[redacted]

Priority FLASH

From: computer@torbmepplinw01.local
To: red@cbc.ca
CC:
Subject: [Alert Desk - Flash] CBC-POL-GOV-VACCINE-MANDATE-TRAVEL

Livelink ID: [redacted] s.68.1
Sent Date: 2021-10-5 7:16 EDT
Received Date: 2021-10-5 19:16 EDT

Flagged by Philip Ling

[redacted] Chris Carter has approved sourcing.***

[redacted]

BG: https://www.cbc.ca/news/politics/federal-government-mandatory-vaccinations-1.6140131

Priority FLASH

--
You received this message because you are subscribed to the Google Groups "Red" group.
To unsubscribe from this group and stop receiving emails from it, send an email to Red+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

From: computer@torbmepplinw01.local
To: red@cbc.ca
CC:
Subject: [Alert Desk - Flash] CBC-POLS-NEW-TRAVEL-VAX-REQUIREMENTS

Livelink ID: [redacted]
Sent Date: 2021-10-29 7:03 EDT
Received Date: 2021-10-29 07:03 EDT

EMBARGO HAS LIFTED:

The Transport Minister will be making an announcement at 1200 ET at Pearson Airport tomorrow.

[redacted] Chris Carter approves sourcing.

[redacted]

Priority FLASH

--
You received this message because you are subscribed to the Google Groups "Red" group.
To unsubscribe from this group and stop receiving emails from it, send an email to Red+unsubscribe@cbc.ca.
To view this discussion on the web visit

From: Sharon Musgrave <sharon.musgrave@cbc.ca>
To: "Desk, Alert" <alertdesk@cbc.ca>, World Report <wr@cbc.ca>
CC:
Subject: [wr] Fwd: [Hill News] Moderna vaccine file

Livelink ID: [redacted]
Sent Date: 2020-12-15 10:43 EST
Received Date: 2020-12-15 10:43 EST

approved by Chris Carter

s.18(b)

s.68.1

Moderna vaccines could arrive in Canada in December

s.16(2)(c)

By David Cochrane

[redacted]

From:	CATHRIN BRADBURY <cathrin.bradbury@cbc.ca>	**Livelink ID:**	
To:	alison.broddle@cbc.ca, amanda.pyle@cbc.ca, andree.lau@cbc.ca, ashley.terry@cbc.ca, brodie.fenlon@cbc.ca, carl.swanston@cbc.ca, cathy.perry@cbc.ca, chad.paulin@cbc.ca, chris.carter@cbc.ca, david.downey@cbc.ca, david.hutton@cbc.ca, derek.stoffel@cbc.ca, drake.fenton@cbc.ca, francis.dsouza@cbc.ca, greg.reaume@cbc.ca, helen.evans@cbc.ca, helen.henderson@cbc.ca, irene.thomaidis@cbc.ca, jennifer.harwood@cbc.ca, joanne.mcpherson@cbc.ca, joseph.ross@cbc.ca, karyn.pugliese@cbc.ca, kenny.yum@cbc.ca, laura.mcisaac@cbc.ca, lianne.elliott@cbc.ca, mari.ito@cbc.ca, marie.caloz@cbc.ca, mark.harrison@cbc.ca, mark.ross@cbc.ca, melanie.verhaeghe@cbc.ca, michael.dick@cbc.ca, michael.gruzuk@cbc.ca, nancy.waugh@cbc.ca, paul.hambleton@cbc.ca, raj.ahluwalia@cbc.ca, seema.patel@cbc.ca, shawna.kelly@cbc.ca, shiral.tobin@cbc.ca, stephanie.coombs@cbc.ca, susan.marjetti@cbc.ca, tim.richards@cbc.ca, tracy.seeley@cbc.ca, treena.wood@cbc.ca	**Sent Date:**	2021-8-24 2:29 EDT
		Received Date:	2021-8-24 14:29 EDT
CC:			
Subject:	Content Meeting agenda for Wednesday August 24.		

Hi all:

We'd like to open the floor to a discussion of how CBC covers the segment of our audience and Canadians who are vaccine hesitant/rejectors.

Paul Hambleton will be there to address questions about balance and fairness around this fraught issue.

Michael Gruzuk shared a note yesterday that asked how we really listen to audiences on this issue. "We had a good conversation about this last week around vaccine-hold-outs, and how we can objectively listen to Canadians without judgement."

If you haven't already, check out the video MG shared from the NYT about vaccine-hesitancy and the reasons of liberty and individualism behind it. It lets the journalism and people speak for themselves. Worth the 7:00.

https://www.youtube.com/watch?v=pd8P12BXebo

I'm hoping for an open and thoughtful conversation about how much or little we tackle the story, and some creative ideas for approaches to our coverage.

If you have additional agenda items please send them to me by 9 am tomorrow

Cathrin

From: CBC Ombud <ombud@cbc.ca>
To: Newsgroup <newsgroup-grp@cbc.ca>
CC:
Subject: Fwd: CBC Response - Letter August 10, 2021 - Coverage of Booster Vaccine - Israel

Livelink ID: [redacted]
Sent Date: 2022-3-28 1:44 EDT
Received Date: 2022-3-28 13:44 EDT

fyi

s.19(1)

Jack Nagler
CBC Ombudsman

s.16(2)(c)

ombud@cbc.ca
www.cbc.ca/ombudsman

CBC Radio-Canada

On my website: Subscribe to reviews

---------- Forwarded message ---------
From: [redacted]
Date: Mon, Mar 28, 2022 at 12:29 PM
Subject: Re: CBC Response - Letter August 10, 2021 - Coverage of Booster Vaccine - Israel
To: PAUL HAMBLETON <paul.hambleton@cbc.ca>
Cc: BRODIE FENLON <brodie.fenlon@cbc.ca>, CBC Ombudsman <ombud@cbc.ca>

Dear Mr Hambleton,
Thank you for investigating the news report about Israel giving a third shot, which caused me considerable concern, and your response, below, which I greatly appreciate.

My apologies for not thanking you sooner.

Sincerely,
[redacted]

On Tuesday, August 10, 2021, 12:47:25 PM EDT, PAUL HAMBLETON <paul.hambleton@cbc.ca> wrote:

Dear [redacted]

Thank you for your email to the Ombudsman's office with a concern about a brief radio news segment you heard on the World this Hour during the day on July 29th.

As Director of Journalistic Standards the Editor in Chief Brodie Fenlon asked me to respond on his behalf.

You wrote:

CBC reported on Israel's decision to give a booster to those 60 years of age and up. The item included a recording of the Prime Minister, Naftali Bennet, explaining the country's difficult and groundbreaking decision. Studies in Israel are showing that the efficacy of the vaccine given by and large over six months ago to seniors, is rapidly waning.

Rather than leaving the story there, or commenting that Israel has been a world leader in the vaccine rollout and jurisdictions the world over have benefited from its groundbreaking research, the item ended with what felt to me to be a punch in the gut. There was a comment questioning whether a third dose was ethical.

I have reviewed this segment and agree with you that the reference to whether some might feel there was an "ethical" issue was not well explained and probably should not have been included in such a short piece.

At that time there were concerns expressed by the WHO, the US President and others about the fact that Israel was proceeding with a possible third shot while other less prosperous nations were still working on the first shot.

My view is if this was relevant to the coverage, then there should have been some proper reporting on where these ethical concerns came from and why, and I have shared this with the programmers.

This was a very short segment, perhaps no more than 40 seconds long in its entirety. On the hourly newscasts, the challenge is always to report the latest news, and provide some context where possible and when necessary. Almost all of the time, this is achieved.

Regretfully, I feel the editors found themselves in the middle in this instance and that there was not enough time devoted to this issue once raised.

I have spoken with the editors involved and reminded them of their responsibilities to tell the stories as simply and cleanly as possible.

Thank you for pointing this out.

Sincerely,
Paul

Paul Hambleton

Director of Journalistic Standards
CBC News

s.16(2)(c)

--
You received this message because you are subscribed to the Google Groups "Newsgroup" group.
To unsubscribe from this group and stop receiving emails from it, send an email to newsgroup-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit

s.16(2)(c)
s.18(b)
s.21(1)(b)
s.68.1

From: PAUL HAMBLETON <paul.hambleton@cbc.ca>
To: ALL CBC NEWS STAFF <all-cbc-news-staff-grp@cbc.ca>
CC:
Subject: A few JSP/COVID related thoughts

Livelink ID:
Sent Date: 2020-12-9 1:12 EST
Received Date: 2020-12-9 13:12 EST

Some things that have come up recently:

[redacted]

Thanks for considering all this.
Paul

Paul Hambleton
Director of Journalistic Standards
CBC News

--
You received this message because you are subscribed to the Google Groups "ALL CBC NEWS STAFF" group.
To unsubscribe from this group and stop receiving emails from it, send an email to all-cbc-news-staff-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

From: Lianne Elliott <lianne.elliott@cbc.ca>

To: adam.miller@cbc.ca, Alice Kristo <alice.kristo@cbc.ca>, Alisha Parchment <alisha.parchment@cbc.ca>, Alison Broddle <alison.broddle@cbc.ca>, Allison Brachman <allison.brachman@cbc.ca>, Amanda Margison <amanda.margison@cbc.ca>, amara.mclaughlin@cbc.ca, Amedeo De Palma <amedeo.de.palma@cbc.ca>, Anand Ram <anand.ram@cbc.ca>, Andreas Wesley <andreas.wesley@cbc.ca>, andree.lau@cbc.ca, Andrew Davidson <andrew.davidson@cbc.ca>, Andrew Ferguson <andrew.ferguson@cbc.ca>, Andrew Pepper <andrew.pepper@cbc.ca>, Angela Hennessy <angela.hennessy@cbc.ca>, Angela Naus <angela.naus@cbc.ca>, Arif Noorani <arif.noorani@cbc.ca>, Ashley Terry <ashley.terry@cbc.ca>, Aubrey Silverberg <aubrey.silverberg@cbc.ca>, avneet.dhillon@cbc.ca, Bertram Schneider <bertram.schneider@cbc.ca>, bhupinder.hundal@cbc.ca, Blake Prendergast <blake.prendergast@cbc.ca>, Brenda Murray <brenda.murray@cbc.ca>, britnei.bilhete@cbc.ca, Brock Wilson <brock.wilson@cbc.ca>, brodie.fenlon@cbc.ca, Catherine Clark <catherine.clark@cbc.ca>, Catherine Gregory <catherine.gregory@cbc.ca>, catherine.legge@cbc.ca, cathrin.bradbury@cbc.ca, cecil.rosner@cbc.ca, Celina Fischer <celina.fischer@cbc.ca>, CHAD PAULIN <chad.paulin@cbc.ca>, charles.fogel@cbc.ca, Cheryl Brown <cheryl.brown@cbc.ca>, Chris Carter <chris.carter@cbc.ca>, christopher.oke@cbc.ca, colleen.ross@cbc.ca, Conrad Collaco <conrad.collaco@cbc.ca>, Daniel Getz <daniel.getz@cbc.ca>, Danielle Greenberg <danielle.greenberg@cbc.ca>, Darcy Hunter <darcy.hunter@cbc.ca>, darrow.macintyre@cbc.ca, David Abrahams <david.abrahams@cbc.ca>, david.f.price@cbc.ca, DAVID HUTTON <david.hutton@cbc.ca>, Dayna Gourley <dayna.gourley@cbc.ca>, deborah.nobes@cbc.ca, Derek DeSouza <derek.desouza@cbc.ca>, Derek Stoffel <derek.stoffel@cbc.ca>, diana.swain@cbc.ca, Diane Pain <diane.pain@cbc.ca>, don.spandier@cbc.ca, earvin.solitario@cbc.ca, elaine.bateman@cbc.ca, Elaine Chau <elaine.chau@cbc.ca>, elizabeth.haggarty@cbc.ca, Erin Boudreau <erin.boudreau@cbc.ca>, ERIN OBOURN <erin.obourn@cbc.ca>, Fiona Christensen <fiona.christensen@cbc.ca>, frances.bedford@cbc.ca, francis.dsouza@cbc.ca, "Froi U." <froilan.untalasco@cbc.ca>, Gary Graves <gary.graves@cbc.ca>, Greg Reaume <greg.reaume@cbc.ca>, Heather Evans <heather.evans@cbc.ca>, Heather Loughran <heather.loughran@cbc.ca>, heather.spiller@cbc.ca, Helen Evans <helen.evans@cbc.ca>, Hilary Walker <hilary.walker@cbc.ca>, Ian Kalushner <ian.kalushner@cbc.ca>, Ilana Banks <ilana.banks@cbc.ca>, IRENE THOMAIDIS <irene.thomaidis@cbc.ca>, james.evans@cbc.ca, jayme.poisson@cbc.ca, JEANANN STEWART <jeanann.stewart@cbc.ca>, Jeff Goldhar <jeff.goldhar@cbc.ca>, jennifer.chevalier@cbc.ca, Jennifer Harwood <jennifer.harwood@cbc.ca>, Jennifer Sheepy <jennifer.sheepy@cbc.ca>, jim.williamson@cbc.ca, John Bowman <john.bowman@cbc.ca>, Jordan Abraham <jordan.abraham@cbc.ca>, kari.vierimaa@cbc.ca, Kathleen Petty <kathleen.petty@cbc.ca>, Kazi Stastna <kazi.stastna@cbc.ca>, Kenneth Sharpe <kenneth.sharpe@cbc.ca>, kit.kolbegger@cbc.ca, lara.chatterjee@cbc.ca, Lara Hindle <lara.hindle@cbc.ca>, Laura Green <laura.green@cbc.ca>, Laura McIsaac <laura.mcisaac@cbc.ca>, Leanne Hazon <leanne.hazon@cbc.ca>, Leiane Cooke <leiane.cooke@cbc.ca>, Lily Boisson <lily.boisson@cbc.ca>, linda.kelly@cbc.ca, Lindsay Tsuji <lindsay.tsuji@cbc.ca>, LISA FENDER <lisa.fender@cbc.ca>, lisa.khoo@cbc.ca, litsa.sourtzis@cbc.ca, Lyndsay Duncombe <lyndsay.duncombe@cbc.ca>, maham.abedi@cbc.ca, MANDY LUK <mandy.luk@cbc.ca>, Mari Ito <mari.ito@cbc.ca>, maria.delorey@cbc.ca, Marie Caloz <marie.caloz@cbc.ca>, Marielle Ortañez Torrefranca <marielle.torrefranca@cbc.ca>, Mark Harrison <mark.harrison@cbc.ca>, Mark Ross <mark.ross@cbc.ca>, Marlene Murphy <marlene.murphy@cbc.ca>, Martina Fitzgerald <martina.fitzgerald@cbc.ca>, meagan.fiddler@cbc.ca, Michael Dick <michael.dick@cbc.ca>, michael.gruzuk@cbc.ca, mike.prokopec@cbc.ca, Nahayat Tizhoosh <nahayat.tizhoosh@cbc.ca>, Nahlah Ayed <nahlah.ayed@cbc.ca>, nancy.kelly@cbc.ca, Nancy Waugh <nancy.waugh@cbc.ca>, Natalie Crowell <natalie.crowell@cbc.ca>, Nelisha Vellani <nelisha.vellani@cbc.ca>, Nick MCCABE LOKOS <nick.mccabe.lokos@cbc.ca>, nicolle.arams@radio-canada.ca, NINA CORFU <nina.corfu@cbc.ca>, Patrick Morrell <patrick.morrell@cbc.ca>, paul.hambleton@cbc.ca, paul.hantiuk@cbc.ca, Paul Moore <paul.moore@cbc.ca>, Paula Waddell <paula.waddell@cbc.ca>, Peter Johnson <peter.johnson@radio-canada.ca>, Raj Ahluwalia <raj.ahluwalia@cbc.ca>, rick.hughes@cbc.ca, rita.tonelli@cbc.ca, ROB EASTON <rob.easton@cbc.ca>, Robert Lack <robert.lack@cbc.ca>, ron.desmoulins@cbc.ca, Roxanna Woloshyn <roxanna.woloshyn@cbc.ca>, Ruth Zowdu <ruth.zowdu@cbc.ca>, Sabrina Fabian <sabrina.fabian@radio-canada.ca>, SCOTT ROBERTS <scott.roberts@cbc.ca>, Sean Brocklehurst <sean.brocklehurst@cbc.ca>, Sean Rombough <sean.rombough@cbc.ca>, Seema Patel <seema.patel@cbc.ca>, Serenity Palia <serenity.palia@cbc.ca>, shannon.higgins@cbc.ca, Sharon Musgrave <sharon.musgrave@cbc.ca>, Shawna Kelly <shawna.kelly@cbc.ca>, Sheila Rider <sheila.rider@cbc.ca>, shona.wolpert@cbc.ca, Silvet Ali <silvet.ali@radio-canada.ca>, Simon Bassett <simon.bassett@cbc.ca>, Spencer Walsh <spencer.walsh@cbc.ca>, steph.brown@cbc.ca, stephanie.coombs@cbc.ca, STEPHANIE DUDLEY <stephanie.dudley@cbc.ca>, Stephanie Jenzer <stephanie.jenzer@cbc.ca>, stephanie.kampf@cbc.ca, Steve Lus <steve.lus@cbc.ca>, Stuart Duncan <stuart.duncan@cbc.ca>, susan treen <susan.treen@cbc.ca>, Tamika Forrester <tamika.forrester@cbc.ca>, Tarannum Kamlani <tarannum.kamlani@cbc.ca>, Terry Auciello <terry.auciello@cbc.ca>, Theresa Duvall <theresa.duvall@cbc.ca>, Timothy Neesam <timothy.neesam@cbc.ca>, tony.von.richter@cbc.ca, Tracy Johnson <tracy.johnson@cbc.ca>, Tracy Seeley <tracy.seeley@cbc.ca>, treena.wood@cbc.ca, tyler.bloomfield@cbc.ca, Valerie Ouellet <valerie.ouellet@radio-canada.ca>, Waqas Chughtai <waqas.chughtai@cbc.ca>, WILLOW SMITH <willow.smith@cbc.ca>, Domestic Bureaus <domestic-bureaus-grp@cbc.ca>, World News Staff <world-news-staff@cbc.ca>, CBCNews Network Assignment <cbcnews-network-assignment-grp@cbc.ca>, WebHealth <webhealth@cbc.ca>, Ken MacIntosh <ken.macintosh@cbc.ca>, Peter Gullage <peter.gullage@cbc.ca>, Lianne Elliott <lianne.elliott@cbc.ca>

CC:

Subject: Editorial priorities: [redacted]on Vaccines

Livelink ID: [redacted]

Sent Date: 2020-12-9 5:06 EST

Received Date: 2020-12-9 17:06 EST

s.16(2)(c)

s.18(b)

s.19(1)

s.68.1

Hi everyone,

[redacted]

Our meeting will be a q&a session -- please come with questions. We can talk about the Covid vaccine coverage, what angles we should be pursuing, what we're missing and how to handle sensitive issues like vaccine hesitancy.

This meeting is open to anyone who is interested -- please share the invite.

Talk tomorrow,
Lianne

s.16(2)(c)

Editorial priorities

When Thu Dec 10, 2020 11:00 – 12:00 Eastern Time - Toronto

Where TOR-4-B-315-Brdrm Bill Dent/Dorina Lica (7) [CFM] (map)

Joining info Join with Google Meet

[redacted]

Join by phone

(US) [redacted]

Who

- Lianne Elliott - organizer
- JEANANN STEWART
- Waqas Chughtai
- Erin Boudreau
- Robert Lack
- Jennifer Sheepy
- Roxanna Woloshyn
- Timothy Neesam
- Nahlah Ayed
- susan treen
- Martina Fitzgerald
- Andrew Ferguson
- cecil.rosner@cbc.ca
- Nancy Waugh
- Ilana Banks
- MANDY LUK
- Jeff Goldhar
- Helen Evans
- Catherine Clark
- Andrew Pepper
- linda.kelly@cbc.ca
- Shawna Kelly
- Lara Hindle
- Hilary Walker
- LISA FENDER
- Lyndsay Duncombe
- Derek Stoffel
- Jordan Abraham
- Lily Boisson
- Angela Naus

- Amedeo De Palma
- michael.gruzuk@cbc.ca
- treena.wood@cbc.ca
- Tracy Seeley
- Don Spandier
- Nelisha Vellani
- Ian Kalushner
- Spencer Walsh
- Nick MCCABE LOKOS
- Alice Kristo
- Valerie Ouellet
- Marie Caloz
- Blake Prendergast
- Sheila Rider
- Allison Brachman
- Andrew Davidson
- adam.miller@cbc.ca
- cathrin.bradbury@cbc.ca
- maria.delorey@cbc.ca
- Derek DeSouza
- Kazi Stastna
- Greg Reaume
- Darcy Hunter
- Celina Fischer
- ERIN OBOURN
- Laura McIsaac
- SCOTT ROBERTS
- Leanne Hazon
- Jennifer Harwood
- rita.tonelli@cbc.ca
- ROB EASTON
- brodie.fenlon@cbc.ca
- rick.hughes@cbc.ca
- Heather Evans
- Simon Bassett
- colleen.ross@cbc.ca
- francis.dsouza@cbc.ca
- IRENE THOMAIDIS

- Brenda Murray
- jim.williamson@cbc.ca
- heather.spiller@cbc.ca
- lisa.khoo@cbc.ca
- Mark Harrison
- Sean Rombough
- CHAD PAULIN
- lara.chatterjee@cbc.ca
- Alison Broddle
- Mark Ross
- WILLOW SMITH
- david.f.price@cbc.ca
- elizabeth.haggarty@cbc.ca
- stephanie.coombs@cbc.ca
- Daniel Getz
- Raj Ahluwalia
- NINA CORFU
- paul.hambleton@cbc.ca
- Patrick Morrell
- nancy.kelly@cbc.ca
- Ashley Terry
- Danielle Greenberg
- Terry Auciello
- Mari Ito
- Chris Carter
- Aubrey Silverberg
- litsa.sourtzis@cbc.ca
- jayme.poisson@cbc.ca
- diana.swain@cbc.ca
- Laura Green
- steph.brown@cbc.ca
- Serenity Palia
- Angela Hennessy
- frances.bedford@cbc.ca
- Sabrina Fabian
- kari.vierimaa@cbc.ca
- Andreas Wesley
- Lindsay Tsuji
- Catherine Gregory

- Seema Patel
- OTTASSIGNMENT
- Sharon Musgrave
- Tracy Johnson
- Peter Johnson
- Local Services Managing Editors
- Ruth Zowdu
- DAVID HUTTON
- avneet.dhillon@cbc.ca
- Cheryl Brown
- deborah.nobes@cbc.ca
- Anand Ram
- meagan.fiddler@cbc.ca
- Theresa Duvall
- bhupinder.hundal@cbc.ca
- Sean Brocklehurst
- Elaine Chau
- shannon.higgins@cbc.ca
- Diane Pain
- Nahayat Tizhoosh
- Stephanie Jenzer
- andree.lau@cbc.ca
- Natalie Crowell
- tyler.bloomfield@cbc.ca
- amara.mclaughlin@cbc.ca
- kit.kolbegger@cbc.ca
- charles.fogel@cbc.ca
- paul.hantiuk@cbc.ca
- John Bowman
- Alisha Parchment
- earvin.solitario@cbc.ca
- Brock Wilson
- Leiane Cooke
- Stuart Duncan
- Team Vertical
- STEPHANIE DUDLEY
- Marielle Ortañez Torrefranca
- Tamika Forrester

- britnei.bilhete@cbc.ca
- WebUGC
- Michael Dick
- james.evans@cbc.ca
- Paula Waddell
- Fiona Christensen
- Dayna Gourley
- Ontario Executives
- Gary Graves
- ron.desmoulins@cbc.ca
- Amanda Margison
- Silvet Ali
- Kathleen Petty
- Bertram Schneider
- Heather Loughran
- tony.von.richter@cbc.ca
- shona.wolpert@cbc.ca
- Steve Lus
- jennifer.chevalier@cbc.ca
- Paul Moore
- Froi U.
- Conrad Collaco
- elaine.bateman@cbc.ca
- darrow.macintyre@cbc.ca
- maham.abedi@cbc.ca
- catherine.legge@cbc.ca
- Kenneth Sharpe
- Tarannum Kamlani
- nicolle.arams@radio-canada.ca
- mike.prokopec@cbc.ca
- stephanie.kampf@cbc.ca
- David Abrahams
- Arif Noorani
- christopher.oke@cbc.ca
- Marlene Murphy

A weekly meeting to discuss editorial priorities for CBC News.

s.18(b)
s.21(1)(b)
s.68.1

Subject: Journalism updates for News, Current Affairs & Local
From: BRODIE FENLON <brodie.fenlon@cbc.ca>
Date: 2/26/2021, 11:28 AM
To: BRODIE FENLON <brodie.fenlon@cbc.ca>
BCC: all-cbc-news-staff-grp@cbc.ca

Hello everyone. I just wanted to share some journalism-related updates for our Division of News, Current Affairs and Local. (It's a long email -- please be sure to expand if it cuts off at the bottom).

COVID-19



A0078910_8-000077

s.18(b)

s.21(1)(b)

s.68.1



A0078910_9-000078

[redacted]

We now have **a new public website** where we aggregate and publish significant corrections or clarifications to our TV and radio news reports and online articles: https://www.cbc.ca/news/corrections-clarifications-1.5893564. Our site mirrors a similar page at Radio-Canada: https://ici.radio-canada.ca/info/mises-au-point

If you have any questions about this, don't hesitate to reach out to **Paul Hambleton**.

s.16(2)(c)
s.18(b)
s.68.1

OMBUDSMAN REVIEWS

It is everyone's responsibility to be aware of the Ombudsman's reviews of our work. There have been five reviews already this year. Each offers an opportunity for us to learn and reflect on our journalism. https://cbc.radio-canada.ca/en/ombudsman

JSP

The review of how we interpret the JSP through an inclusive lens continues at CBC. The committee members are doing meaningful work and have asked for more time as they dig into areas of crime and police reporting, POV & Opinion, social media & conflict of interest, interviews, impartiality and how to broaden input on our Language Guide. We expect their recommendations in the spring.

Separately, I wanted to remind everyone that there's an online training module for the JSP here: [redacted]

NEWSGATHERING

Assigning, gathering and producing stories that resonate with a changing Canada is our mission. The demands on our newsgathering operation are as intense as ever. We are committed to investing in domestic and foreign news where we can to meet these demands. So stay tuned next week for some important staffing announcements involving our New York/UN bureau, London UK, and the network reporter and producer roles in the North. Very exciting.

DIGITAL SUCCESS

[redacted]

BIG GETS, SCOOPS, IMPORTANT STORIES

When Kamala Harris was elected vice-president in November, her connection to Canada from her high-school years spent in Montreal were already well-known, and some of her former classmates had spoken to the media, including CBC. Less well-known, however, was that Harris's aunt and uncle live in Canada — in fact, Harris referred to her aunt during her speech to the Democratic National Convention last summer. That reference and another mention in a profile caught the attention of *Rosemary Barton Live* producer **Philip Ling**. He undertook a search for them and found them, in the GTA, for their first public interview. When he reached them to ask if they'd come on RBL they said sure, and that no one else had ever asked them to talk about their niece.

It was a great story & interview just waiting to be found. All it took was some gumption, some digging, some asking.

Phil is moving to a new role as a Senior Producer in our Parliamentary Bureau, but he has at least one more big get for RBL before then: Anthony Blinken, the new U.S. Secretary of State — the result of a months-long chase. Watch the full interview this Sunday.

That kind of journalistic hustle is evident across our division. I asked managers to send me some recent examples of exemplary work, big gets and scoops. Again, we can never celebrate it all in one place. There are too many examples. But here are a few (in case you're looking for a few excellent reads, watches or listens this weekend):

- CBC Calgary reporter **Meghan Grant** broke a story in January giving detailed accounts from seven BIPOC current and former members of the Calgary Fire Department detailing an "extremely toxic environment" in the fire halls, alleging years of racist abuse and two buried workplace reviews. The story, headlined **Trauma at the Station**, left the competition scrambling to match — including the New York Times weeks later. After her story was published, the chief was forced to address the allegations publicly and before a city council committee, the mayor promised to push for the release of the reviews



s.18(b)

s.68.1

[redacted]

Producer **Madeline McNair, Dave Rae** and Jorge worked under direction of the iUnit and in coordination with CBC Edmonton's **Paul Moore**, **Janice Johnston, Raffy Boudjikanian** and **Andre Mayer** in Toronto to produce versions for the National, CBC Edmonton, Radio and TV, CBC News Network, CBCNews.ca and Front Burner. See In the shadow of her killer's verdict, Cindy Gladue's family wants to reclaim her humanity

- Inuit in Canada's eastern Arctic are at a pivotal point in deciding the fate of one of the most Northern mines in the world. Baffinland Iron Mines Corporation has been mining iron ore since 2014 after striking a deal with Inuit to dig on their land. But now as the mine seeks expansion, High Arctic communities are torn between keeping the mine's vital jobs and the risk to the land and the wildlife on which many rely. **Pauline Pemik** and **Nick Murray** flew over a thousand kilometres north of Iqaluit, and then Nick drove 10 hours (320 kilometres) roundtrip on a snowmobile across difficult Arctic terrain to gather visuals of the affected area.

s.18(b)
s.68.1

- **The Current** landed a Canadian broadcast exclusive with Bill Gates, tackling climate change and the COVID-19 pandemic and what exactly he thinks about some of the wild conspiracy theories floating around about him. Rollout was comprehensive across all CBC platforms, including social video, stories on The National and NN and two digital stories.

- One of CBC BC's newest journalists, **Ashley Moliere**, weaved her own personal experience into this story detailing the life of Mifflin Gibbs, the first Black person elected to public office in B.C., who we never hear about in schools. It was created by **Andrew McManus** and his team, and it's stunning. Here's the video version: https://www.cbc.ca/player/play/1864684611856

- CBC recognized Black History Month throughout February with a wide range of programming across all platforms featuring Black creators, storytellers and changemakers, curated and discoverable in one destination, CBC's Being Black in Canada, Truly a "One CBC" success with a commitment that will continue, reflecting all communities across the country. Huge credit to CBC News' **Tamika Forrester**, **Asha Tomlinson**, **Ghazala Malik** and **Nathaniel Smith** for producing a series of eight features on Canadian Black change-makers and leaders for Canada Tonight with Ginella Massa, The National and the new Being Black in Canada Instagram. On Saturday, Asha hosts a special half-hour News special on CBC News Network and CBC GEM produced by **Xavine Bryan**. Tune in at 16:30, 21:30 and 23:30 ET.

s.18(b)
s.68.1

- On Feb. 6, the day of the U.S. Capitol riots, **As It Happens** proved again that it shines in breaking news situations, by reaching voices at the centre of the story. When most other media were still talking to reporters and analysts, we reached Black Democratic Congresswoman Bonnie Watson Coleman, who was forced to hide from the crowd that stormed the Capitol building — and who told us the riots were "domestic terrorism ... incited by the president of the United States." (Note: a week later, we went back to Rep. Watson Coleman when she had tested positive for COVID-19, which she believes she contracted while sheltering during that unprecedented event with some Republican colleagues who weren't wearing masks.)

- **Emily Chung**, **Tashauna Reid** and **Alice Hopton** of our Science Unit did a multiplatform report about an online store that launched in Ontario selling groceries and household items from Loblaws in reusable packaging. And whether it's the large-scale change needed to alter consumer behaviour. The story led the website for much of the day, drawing thousands of readers and sparking people to share advice and debate whether reusable packaging could work. It's a great example of TV and digital pieces complimenting each other and providing viewers with context in different ways. And our audience obviously appreciates that.

- CBC Ottawa got out in front of a story about a proposed development called Tewin, which is a partnership between the city, a developer and the Algonquins of Ontario. The station owned the coverage for weeks. The reporting was led by Ottawa's municipal reporting team, **Kate Porter** and **Joanne Chianello**, with support from **Jorge Barrera** from the Indigenous team and producer **Jennifer Chevalier**.

- **Jonathan Montpetit**'s examination of the anti-mask movement for CBC Quebec provided the first comprehensive analysis of the radicalization of COVID-19 conspiracy theorists in the province, and

A0078910_14-000083

among the first anywhere in Canada. [redacted]

- This Valentine's Day love story by **Bonnie Allen** with animation by illustrator **Steve Silcox** from Winnipeg is magic. Visually and emotionally powerful. The story was made possible through CBC Saskatchewan's Storytelling Project under **Natascia Lypny**. The story aired on The National and all social media platforms, along with rollout on digital and network radio. If you watch one thing today, this is it: https://www.cbc.ca/player/play/1859148355515

s.18(b)

s.68.1

- **White Coat Black Art** launched its high-impact series in February with inspiring stories from a diverse range of people across Canada on the radio and in this longform digital feature: Prescription for Resilience: Coping with COVID. From a grandmother who discovers purpose and connection through Urdu lessons, to a CFL player grappling with a career on hold and death of a loved one and a 97-year-old who finds hope in daily walks, the project features 14 stories and truly reflects Canadians back to themselves. A highlight is the delightful video from 97-year-old Sheila White, with her tips on staying strong. It had huge engagement on Facebook — at last count nearly 1 million video views on that platform alone. The project will continue this weekend and link up with Unreserved focusing on how Indigenous communities are staying connected and finding culture during the pandemic.

- CBC London continues to start conversations that are leading to actions by leaders. London's newest reporter/editor, **Sara Jabakhanji,** tackled the story of a racist billboard at a bar. She spoke to multiple Asian Londoners and pursued local leaders. [redacted]

A0078910_15-000084

- It's a haunting sight in downtown Sudbury, and one that could easily be duplicated in cities across Canada. What started as a single cross put up by a mother whose son died of an overdose has grown into a large memorial site with more than 150 crosses, all in memory of people who have died of overdoses. In this cross-platform, cross-cultural coverage, CBC Sudbury's **Sarah MacMillan** brings us the stories of loved ones grieving together, and their hope that this public display will lead to change before losing a generation to the opioid crisis. Radio-Canada partnered with us together moving visuals, and Sarah filed to digital, radio current affairs (including talk/tape across Ontario), World This Weekend and The National.

- As we continue our push to reflect contemporary Canada, **Syndicated Audio** has partnered with CBC BC on "Urban Nations" and that popular BC audio and digital offer is now being broadcast on afternoon radio shows across the country. **Wawmeesh Hamilton** focuses on the Indigenous populations that "don't live at home," and whose experiences of what it's like to live in urban settings across Canada are often untold. [redacted] Urban Nations is a great example of how Syndicated Audio is working to amplify the incredible content being produced in regions across the country, while introducing our audiences to new voices and authentically sharing stories that otherwise would not be told.

- **Sophia Harris**, **Dianne Buckner** and **Marc Baby** of our Business Unit revealed that nearly half of the 10 million entries into Canada since March 2020 were made by commercial truck drivers crossing by land — a group for whom Ottawa's new travel rules do not apply. We got access to this group of frontline workers we don't normally hear from. The story got picked up by other media outlets.

- **Briar Stewart** got unique access to an outreach program involving police officers in Abbotsford and they showed us first hand what drug decriminalization looks like, as they have already adopted that model there. The piece aired the same week that Vancouver and Ottawa started discussions on decriminalization, and it coincided with the vote on the issue by Montreal city council.

s.18(b)

s.68.1

Amazing work. Have a great weekend,
Brodie

--

Brodie Fenlon
Editor In Chief, Executive Director of Daily News
CBC News
Pronouns: he and him
@brodiefenlon

Amanda Pyle
Executive Assistant
amanda.pyle@cbc.ca

--

You received this message because you are subscribed to the Google Groups "ALL CBC NEWS STAFF" group.

s.16(2)(c)

To unsubscribe from this group and stop receiving emails from it, send an email to all-cbc-news-staff-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

A0078910_18-000087

s.18(b)

s.68.1

Subject: Notes on protests coverage
From: George Achi <george.achi@cbc.ca>
Date: 1/27/2022, 4:21 PM
To: George Achi <george.achi@cbc.ca>
BCC: all-cbc-news-staff-grp@cbc.ca

Hi all, this is a note for everyone covering the various protests that started with the trucker convoy. Thank you so much for all your work in the past few days producing robust journalism around this.

Please take a couple of minutes to consider the following guidance as we go forward.



A0078910_19-000088

[redacted]

Please take care. It is an important story and we will continue to cover it. But we must do so safely, reporting with care and precision.

s.16(2)(c)
s.18(b)
s.68.1

--

George Achi (he/him)
Director of Journalistic Standards
and Public Trust
-
CBC News

--

You received this message because you are subscribed to the Google Groups "ALL CBC NEWS STAFF" group.
To unsubscribe from this group and stop receiving emails from it, send an email to all-cbc-news-staff-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

From: BRODIE FENLON <brodie.fenlon@cbc.ca>
To: BRODIE FENLON <brodie.fenlon@cbc.ca>
CC:
Subject: Our role as the pandemic worsens

Livelink ID: [redacted]
Sent Date: 2021-4-16 4:33 EDT
Received Date: 2021-4-16 16:33 EDT

s.16(2)(c)
s.18(b)
s.21(1)(b)
s.68.1

Hi everyone,

As we head into the weekend, I thought it would be a good moment to reinforce the importance of your work and the leadership role that CBC News, Current Affairs and Local is playing during this pandemic.

The news is not great right now.

Some provinces and territories are looking at a rise in caseloads that will make other spikes look easy. We are seeing COVID-19 show up in clusters in parts of the country that were previously spared. We are learning about deeply worrying projections that will put an unprecedented strain on parts of our healthcare system.

Atlantic Canada, in its now famous bubble, still seems to be holding strong. Let's hope that continues.

Elsewhere though, there is a palpable fatigue among Canadians after more than a year in this crisis, with the realization that we are not turning the corners we thought we would by now. It's hard on everyone. And it is hard on us too. We live in these communities and we are all impacted.

Yes, vaccines are coming, but they are not coming fast enough for so many people facing the hard realities of having their lives turned upside down by job losses and job pauses, home schooling, closures, illness and death.

Being a journalist at this time is especially challenging.

[redacted]

We have done some remarkable journalism throughout this health crisis. This note is to tell you again how important your work is, and how unique our role remains in these unprecedented times.

Thank you,

Brodie

--
Brodie Fenlon
Editor In Chief, Executive Director of Daily News
CBC News
Pronouns: he and him
@brodiefenlon

Amanda Pyle
Executive Assistant
amanda.pyle@cbc.ca

--
You received this message because you are subscribed to the Google Groups "ALL CBC NEWS STAFF" group.
To unsubscribe from this group and stop receiving emails from it, send an email to all-cbc-news-staff-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit [redacted]

From: BRODIE FENLON <brodie.fenlon@cbc.ca>

To: Alison Broddle <alison.broddle@cbc.ca>, Amanda Pyle <amanda.pyle@cbc.ca>, ANDREE LAU <andree.lau@cbc.ca>, Anita Lasebnik <anita.lasebnik@cbc.ca>, ANNI KELLY <anni.kelly@cbc.ca>, Carl Swanston <carl.swanston@cbc.ca>, Catherine Gregory <catherine.gregory@cbc.ca>, CATHRIN BRADBURY <cathrin.bradbury@cbc.ca>, Cathy Perry <cathy.perry@cbc.ca>, Chris Carter <chris.carter@cbc.ca>, David Downey <david.downey@cbc.ca>, Erin Knoll <erin.knoll@cbc.ca>, Francis D'Souza <francis.dsouza@cbc.ca>, Greg Reaume <greg.reaume@cbc.ca>, Jennifer Harwood <jennifer.harwood@cbc.ca>, Jennifer Rebello <jennifer.rebello@cbc.ca>, Joanne McPherson <joanne.mcpherson@cbc.ca>, KATIE WARING <katie.waring@cbc.ca>, Kelly Dexter <kelly.dexter@cbc.ca>, KENNY YUM <kenny.yum@cbc.ca>, Laura McIsaac <laura.mcisaac@cbc.ca>, MARIA DELOREY <maria.delorey@cbc.ca>, MICHAEL GRUZUK <michael.gruzuk@cbc.ca>, Natalie Sheehan <natalie.sheehan@cbc.ca>, PAUL HAMBLETON <paul.hambleton@cbc.ca>, Seema Patel <seema.patel@cbc.ca>, Serenity Palia <serenity.palia@cbc.ca>, Susan Marjetti <susan.marjetti@cbc.ca>, Tracy Seeley <tracy.seeley@cbc.ca>, Melissa Mercer <melissa.mercer@cbc.ca>, Sharon Easby <sharon.Easby@cbc.ca>

CC:

Subject: Q4 here we come!

Livelink ID:

Sent Date: 2021-1-4 7:45 EST

Received Date: 2021-1-4 07:45 EST

s.18(b)

s.21(1)(b)

s.68.1

s.16(2)(c)

Good morning and Happy New Year leadership team!

I hope you, like me, got some down time over the holidays. Considering we're in the middle of the worst pandemic in a century, it was blessedly quiet. Please help me thank everyone who carried the ball for us over the last two weeks.

I am going to be largely out of the picture this week and next with the CRTC prep and hearing. I may be slower to respond to you than normal. I may need to lean on you for help even more than I already do. It's going to be intense. Thank you in advance.

Here's some housekeeping and top-of-mind network news priorities for the next three months as we wrap up the fiscal. If you have questions or anything here surprises you, don't hesitate to ask me or your colleagues. As you can see, we have a lot going on!

HOUSEKEEPING

METRICS:

CANADA:

COVID COVERAGE: There have been several notes to audience relations asking for detailed tracking of vaccinations.

OMBUDSMAN COMPLAINT RESPONSES: They are so demanding, I know. We want to beat the 20-day limit whenever we can. And huge props to those of you who respond to questions & concerns that aren't required by the Ombudsman. You help us win people over, one at a time.

NEWS NEXT: It's this Wednesday at 1 p.m. ET. Joanne M is coordinating. Looking forward to it!

Q4 PRIORITIES / MUST-DOs

Here's to a great, busy and exciting quarter ahead. Welcome back!

Brodie

s.18(b)

s.68.1

From: CBC Ombud <ombud@cbc.ca>
To: [redacted]
CC: BRODIE FENLON <brodie.fenlon@cbc.ca>, Mark Harrison <mark.harrison@cbc.ca>
Subject: Re: CBC News - Ombuds Complaint [redacted]

Livelink ID: [redacted]
Sent Date: 2022-8-10 9:49 EDT
Received Date: 2022-8-10 09:49 EDT

Dear [redacted] s.16(2)(c)

I will conduct a review as soon as possible and share the findings with you and the programmers involved.

Please consult the Complaint Review Process on my website, so that you will be aware of the public nature of the review. Point 10 states that my reviews are posted to my website and that complainants will be identified.

Note also that I conduct my reviews in chronological order. There are currently 23 ahead of yours.

Sincerely,

Jack Nagler
CBC Ombudsman
ombud@cbc.ca
www.cbc.ca/ombudsman

CBC Radio-Canada

On my website: Subscribe to reviews

On Tue, Aug 9, 2022 at 3:36 PM [redacted] wrote:

I want to make it EXTREMELY clear that the original piece and the response are entirely UNACCEPTABLE.

This is no better than platforming antaskers and vaxers uncritically.

Well over 43,000 people died of covid in Canada.

30 to 40% of non-hospitalized people with covid develop long Covid. Each infection increases the risk of long Covid. And for the most recent dominant variants each reinfection also weakens people's immune response to covid.

Continuing to insist that the first infection is likely the worst, implying the others will be less severe. Is fucking dangerous.

My concerns are less at ease now than before I read that terrible, dangerous covid misinformation the CBC published, and the EP is doubling down on below.

Kindly relook at this issue. I certainly will continue to push back against this dangerous nonsense with every tool available.

Shame on Mark and his team.

Sent from my iPhone

> On Aug 9, 2022, at 12:21 PM, Mark Harrison <mark.harrison@cbc.ca> wrote:
>
> [redacted]
>
> Dear [redacted]
>
> I am writing in response to your email of July 17 addressed to CBC Ombudsman, Jack Nagler, drawing our attention to what you see as "misleading and factually wrong" information in a CBCNews.ca Health page story posted earlier that day under the headline, "You'll likely catch COVID-19 again and again. Will each round feel milder?" In fact, you wrote, "repeated infections seem to weaken the immune response."
>
> Since I supervise the CBC News Health Unit, Brodie Fenlon, Editor in Chief of CBC News, asked me to reply to you directly.
>
> Let me say immediately that I regret you are disappointed in CBC, but, respectfully, your view of the story is not one I share. I'll explain why I say that.
>
> News stories about continuing events are incremental. Each one adding new information, building on what we already know. And that's what this story does. Since the pandemic swept across the country, we have published hundreds of stories, each one adding new information to refine our knowledge of a persistent virus that has killed tens of thousands of Canadians and sickened millions.
>
> Some scientists once spoke hopefully that herd immunity through infection or diligent vaccination programs would see the pandemic soon peter out. It hasn't as the virus continues to infect tens of thousands every week in what is described as the virus' seventh wave. What we are now seeing is that "reinfections are the norm." With that starting point, the story looks at why reinfection is now common and asks if future infections will be milder than the first? Good question. But the answer it says is "hazy" and goes on to speak with experts who explain why the answer is not clear.
>
> You wrote that the story is "wrong" because it reports that "repeat COVID infections provide a lasting immune response." It does not. In fact, while the headline asks if each round will feel milder, immediately below that the story's sub-headline adds, while "reinfection should get easier for healthy adults," it cautions, "scientists say infection still comes with risks." The story that follows explains why.
>
> Science rarely offers black and white answers, and this is no exception. The story quotes Dr. Allison McGeer, a well-known infectious disease specialist and

professor at the University of Toronto's Dalla Lana School of Public Health, saying that the first COVID infection "probably – not invariably, but probably – is going to be the worst." Dr. McGeer is not alone in that view. Other scientists in the field CBC spoke with agreed, including Dr. Angela Rasmussen, a virologist with the University of Saskatchewan's Vaccine and Infectious Disease Organization, who said "from all the literature I've seen" when reinfections do occur, "they're not usually worse."

While that reflects the consensus view of the scientists we spoke with in preparing this story, there are risks. Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security, warned that "not every second or third infection is going to be benign – and that's particularly true when you're dealing with higher-risk populations." He noted that while repeat infections should feel milder, it's important to keep in mind age, medical history and "shifting risk factors for severe disease" – things like gaining a lot of weight or developing diabetes or becoming immunocompromised.

Reading the story, I think you will find it accurately reports the consensus view of respected scientists who are recognized experts in their field as well as acknowledging there are other views. But that there are different views does not mean that this story is wrong or misleading. Yes, a SARS-CoV-2 infection is risky anytime, but to quote respected authorities saying that for healthy adults, their first infection will probably be the worst, is neither misinformation nor irresponsible.

I appreciated reading your comments, and I hope my reply has eased your concerns.

Sincerely,

Mark Harrison
Executive Producer
Health Unit.
CBC News

Cc. Jack Nagler, CBC Ombudsman
Brodie Fenlon, Editor in Chief, CBC News

From:	[redacted]	**Livelink ID:**	[redacted]
To:	Mark Harrison <mark.harrison@cbc.ca>	**Sent Date:**	2022-2-7 5:31 EST
CC:	CBC Ombud <cbcombud@cbc.ca>, Office of the General Manager and Editor in Chief <officeofgm@cbc.ca>	**Received Date:**	2022-2-7 17:31 EST
Subject:	Re: CBC News - Ombudsman Complaint/[redacted]		

CBC has twisted every Covid-19 related story I have read in the last 2 years. You have manipulated your articles to serve a narrative that is based on lies and meant to control Canadians. You have encouraged hate towards the unvaccinated by repeatedly blaming the unvaxxed for the pandemic and promoting ideas that suggest they don't deserve to go to school and work and should have other fundamental rights removed. This is absolutely disgusting.

Why is CBC continuously posting articles that depict truckers as violent and unreasonable??? Why aren't you talking about the hundreds of thousands of Canadians who have been discriminated against by employers, friends and family for their personal medical decision to refuse the Covid-19 experimental drug? And yes. It is experimental. It was only approved under emergency measures and didn't go through the Gold Standard. Why don't you publish data about how many Canadians caught Covid within days of being vaccinated? Why don't you question Celine Dion about whether she got vaccinated and what might have caused her severe muscles spams?

Why don't you write an article about unvaxxed employees being put on unpaid leave and therefore not being eligible for unemployment insurance, who were working from home or up until then providing regular negative rapid antigen tests while their infected vaccinated colleagues spread Omicron around the office?

Why don't you write an article about the millions of Canadians who DID NOT WANT the vaccine but were COERCED into taking it fearing they would lose their job and not be able to feed their family? Why don't you publish an article on Canadians who have lost their jobs, and homes and can't feed their family because of the lockdowns and again because of losing their jobs to medical discriminations? Why don't you write an article about the thousands of employers whose fields were not even mandated who are blatantly discriminating against the unvaxxed by making the Covid-19 vaccination a requirement of employment? Why don't you report on the hundreds of thousands of employers who are systematically declining employee's religious requests for exemptions? Why don't you report on the thousand doctors who are censored and threatened by their college if they don't agree with the narrative?

Why don't you write a story about how snipers with their big guns all over Ottawa are threatening the lives and food supplies of peaceful freedom loving truckers who are standing for all of us who have been telling you and the government that we don't want your Covid-19 vaccine. Why don't you clarify in your articles that the extremely rare swastika signs and confederation flag you spotted at any of the Freedom rallies were not to promote fascism and segregation but to accuse Justin Trudeau of imposing fascist measures on the population and to condemn his hate speech and segregation. Justin Trudeau is the tyrant. Why don't you write about that???

Why was CBC adamant at warning of possible violence during this week's peace loving freedom rallies but totally failed to mention that the man with a smoke bomb was out there to hurt peaceful demonstrators.

Why don't you report on how Justin Trudeau is conveniently isolating instead of meeting truckers? Why don't you report on his association with the World Health Economic Forum and the Event 201 rehearsal in October 2019? Why don't you report on today's beginning of the Nuremberg 2 trial led by German lawyer Dr. Reiner Fuellmich in which he is named?

https://www.instagram.com/p/CZm1UQDDCyX/

YOU ARE PART OF THE PROBLEM. NOT THE SOLUTION. YOU ARE THE BULLY. STOP HARASSING THE UNVAXXED AND PROMOTING HATESPEECH.

Best,

[redacted]

On Mon, Feb 7, 2022 at 4:39 PM Mark Harrison <mark.harrison@cbc.ca> wrote:

[redacted]

Dear [redacted]

Thank you for your email of January 24 addressed to Jack Nagler, CBC Ombudsman, about an article we published which you said contained misleading information.

Since I supervise the CBC News Science and Environment unit, Brodie Fenlon, Editor in Chief of CBC News, asked me to reply to you directly.

I appreciate your taking the time to write to us. And I regret that you are disappointed in CBC. However, respectfully, your view of the story is certainly not one I share. Please allow me to explain why I say that.

The story, COVID 19 can wreak havoc on your body. So will it cause health issues down the road?, was about the longer term health effects affecting some people who have been infected with SARS-CoV-2.

You suggested that these are adverse effects of an "experimental vaccine."

To be clear, we have reported on adverse vaccine effects extensively in the past. Here are just two examples: Still worried about getting a vaccine for COVID 19? Here's how to understand the rare, but real risks and Ontario man speaks out after father has severe stroke from rare blood clot following AstraZeneca vaccine.

However adverse effects from a vaccination and health effects following a COVID 19 illness are very different and separate things.

As the article said:

"We've already shown this virus, even in the acute stage, does have impact on the brain and on our central organs like the heart, and pancreas and areas where other viral infections have caused longer-term inflammatory changes that have led to chronic disease," said Dr. Cory Neudorf, the public health, health systems and social policy impacts pillar co-lead for CoVaRR-Net, a team of Canadian researchers who banded together during the pandemic.

In fact, longer term health effects from COVID infections were observed before vaccines were even made available.

I would also add that there is very clear evidence that vaccines protect against serious illness and death, especially among older age groups.

It's true that many people who are infected with the virus -- probably the vast majority -- do not suffer lingering health effects. But with so many people, being infected there are real concerns for the ones who do.

On careful reading, I think you will find that there is nothing in the story to support your allegation that it is "misleading" or contains "misinformation."

Thank you again for your email. I hope my reply has reassured you of the continuing integrity of our news service.

Sincerely,

Mark Harrison
Executive Producer
CBC News Content Units

Cc. Jack Nagler, CBC Ombudsperson
Brodie Fenlon, Editor in Chief, CBC News

From: BRODIE FENLON <brodie.fenlon@cbc.ca>

To: Local Services Managing Editors <local-services-managing-editors-grp@cbc.ca>, Daily News Managers <daily-news-managers@cbc.ca>, John Bertrand <john.bertrand@cbc.ca>, Johnny Michel <johnny.michel@cbc.ca>, Meredith Dellandrea <meredith.dellandrea@cbc.ca>, MERVIN BRASS <mervin.brass@cbc.ca>, Ruth Zowdu <ruth.zowdu@cbc.ca>, Susan Marjetti <susan.marjetti@cbc.ca>, Joanne McPherson <joanne.mcpherson@cbc.ca>, KENNY YUM <kenny.yum@cbc.ca>, Catherine Gregory <catherine.gregory@cbc.ca>, PAUL HAMBLETON <paul.hambleton@cbc.ca>, Carl Swanston <carl.swanston@cbc.ca>, David Downey <david.downey@cbc.ca>, Marie Caloz <marie.caloz@cbc.ca>

CC:

Subject: Some journalism notes for managers

Livelink ID:

Sent Date: 2021-10-29 4:41 EDT

Received Date: 2021-10-29 16:41 EDT

s.18(b)

s.21(1)(b)

s.68.1

s.16(2)(c)

Hello managers,

I wanted to share a few updates on some journalism matters (and a bonus "retirements" update). If you could please reinforce the journalism stuff with your leaders, I'd be grateful.

JOURNALISTS & OUTSIDE APPEARANCES

A reminder that before any CBC journalist appears on an outside panel, podcast or speaking event, they must get permission from their manager.

Bigger appearances such as keynote speeches, panel appearances, MC events and interviews must be logged by Paul Hambleton's office. Use this link. Smaller appearances (classroom visits, alma mater shoutouts, teaching visits, interviews) don't need to be tracked but still require approval.

We publish a list of all appearances here: https://www.cbc.ca/news/public-appearances-1.4969965

When approving these appearances, it's important that our employees understand they can speak about their own experiences, but never speak for the CBC or CBC News. They should be very careful when discussing internal matters of debate. As always, they are bound by the principles of the JSP: balances, fairness, accuracy, impartiality and integrity.

BBC PLAN FOR 'FAIR, ACCURATE AND UNBIASED CONTENT'

Hot off the presses and likely of interest to you:

"The BBC has today announced sweeping changes to further raise standards across the organisation and challenge claims of bias. It has published a 10-point plan focused on impartiality, editorial standards and whistleblowing designed to help develop and safeguard staff and improve output across all BBC services."

More here: https://www.bbc.co.uk/mediacentre/2021/bbc-outlines-push-for-fair-accurate-and-unbiased-content

RETIREMENTS

Some big retirements this week. It's hard to keep track of departures across our division, but these are a few I know about and some good "related content":

- Carole MacNeil signed off on Tuesday (https://www.cbc.ca/player/play/1967929923517).
- Andrew Ferguson, Executive Producer on CBC News Network, says farewell today. Tribute videos here (7:04) and here (21:23).
- Ted Blades signs off today from On The Go. He wrote a great piece about his career.
- Greg Rasmussen ends his long reporting career with us today in Vancouver.
- Angela Antle is retiring from CBC, after a stellar career working on programming with CBC Newfoundland and Labrador, CBC Radio and bringing the stories of independent producers to CBC television and CBC Gem.

Thanks and have a good weekend!

Brodie
--
Brodie Fenlon
Editor In Chief, Executive Director of Daily News
CBC News
Pronouns: he and him
@brodiefenlon

Amanda Pyle
Executive Assistant
amanda.pyle@cbc.ca
--
You received this message because you are subscribed to the Google Groups "Daily News Managers" group.
To unsubscribe from this group and stop receiving emails from it, send an email to daily-news-managers+unsubscribe@cbc.ca.
To view this discussion on the web visit

From:	CBC Ombud <ombud@cbc.ca>	**Livelink ID:**	
To:	Karen Rucas <krahome@rogers.com>	**Sent Date:**	2021-10-4 10:45 EDT
CC:	BRODIE FENLON <brodie.fenlon@cbc.ca>, Don Spandier <don.spandier@cbc.ca>	**Received Date:**	2021-10-4 10:45 EDT
Subject:	Re: Worldwide coverage of COVID-19		

s.16(2)(c)

Dear Ms. Rucas,

It is evident that you would like CBC News to be providing very different coverage of COVID-19 and vaccinations than you are seeing.

However, that does not mean that CBC's coverage has been biased or inaccurate.

There is a great deal of information that can be found online which is rather unreliable. For instance, you have claimed in a couple of your emails that Japan has approved use of Ivermectin for treatment of COVID. That is untrue. Similarly, there is zero evidence at the moment that Merck's new proposed treatment drug is simply a repurposed, re-named Ivermectin.

On the other matters, I have told you that as Ombudsman I have no say in setting editorial priorities for CBC News. I understand that you were able to express your concerns about those priorities in a phone conversation with Don Spandier.

The expectation I have for CBC is that they report information which is verified and/or properly attributed. You are welcome to file a complaint about a particular CBC story that you believe fails to do that. But this office was not created to validate or invalidate information that you have encountered elsewhere and find compelling.

Sincerely,

Jack Nagler
CBC Ombudsman
ombud@cbc.ca
www.cbc.ca/ombudsman

CBC Radio-Canada

On my website: Subscribe to reviews

On Mon, Oct 4, 2021 at 8:31 AM Karen Rucas <krahome@rogers.com> wrote:

> Dear Mr. Fenlon and Mr. Nagler,
>
> Here are just a few articles that represent news from around the world with respect to how other countries are managing the coronavirus situation, yet these stories don't ever see the light of day on CBC. I check my newsfeed regularly.
>
> - Norway DROPS All Restrictions And Chooses To LIVE With Covid - here
> - Norway reclassifies Covid-19: No more dangerous than ordinary flu here
> - Japan to lift all coronavirus emergency steps nationwide - Guelph News here
> - Japan green lights Ivermectin here
> - Denmark: https://www.cityam.com/denmark-declares-epidemic-under-control-as-it-downgrades-covid-19/
> - Turkey: https://www.reuters.com/world/middle-east/turkeys-erdogan-says-easing-covid-19-restrictions-further-july-2021-06-21/
> - Worldwide Declaration that more than 5200 physicians and scientists have already
>
> Merck & CBC's Story
>
> On another note, through my own research (I'm not a journalist) **Health Canada informed me that Merck discredited its own off-patent Ivermectin** as a treatment for COVID-19; that's why it is not approved for use in Canada to treat C19, yet it's approved in Japan and in 36 other countries. Ivermectin, however, does work as an anti-viral and anti-inflammatory and has seen success in over 65 trials to treat C19 around the world.
>
> Coincidentally, however, Merck agreed to a manufacturing partnership with Johnson & Johnson to boost production of the latter's Covid vaccine. And, as CBC announced just recently, Merck is awaiting EUA for its "new" anti-viral pill called molnupiravir! *Doesn't this bit of news peak your interest as a journalist?* **Canadians have suffered and died without early treatment with Ivermectin because of Merck's conflict of interest, *not once but twice!*** *And, aren't you even a bit curious as to what is in this "new" pill? Maybe ivermectin re-packaged?*
>
> *Let's see how Merck fares in the courts. Here's one story about a case against Merck wrt Vioxx; and this case* where the court case, United States v. Merck & Co., stems from claims by two former Merck scientists that Merck **"fraudulently misled** the government and omitted, concealed, and adulterated material information regarding the efficacy of its mumps vaccine in violation of the FCA [False Claims Act]."
>
> **How did CBC misinform the public?**

The CBC news recently covered the story regarding Merck's "new" oral anti-viral pill called molnupiravir. The CBC story did not mention that Merck also produces Ivermectin (you know, that "horse-deworming" medication that CBC was trashing not but a week ago!) and, worse still, the CBC story continued to tout the efficacy rate of the vaccines at 95% (RRR) when Israel acknowledges that the efficacy rate (RRR) of Pfizer is below 39% against the delta variant. To add insult to injury, Pfizer's own test results shows that the ARR (absolute risk reduction) is about 1%. Here's the important stuff that any journalist worth their salt should have delivered:

s.16(2)(c)

> The FDA guideline entitled, Communicating Risks and Benefits, indicates that "***Provide absolute risks, not just relative risks. Patients are unduly influenced when risk information is presented using a relative risk approach; this can result in suboptimal decisions. Thus, an absolute risk format should be used.***"

Canadians are being fed a steady diet of misinformation and lack of information by the CBC Broadcasting network. It must stop.

I must ask the obvious question: Is CBC purposely suppressing specific news stories about:

1) the true efficacy of the C19 vaccines?

2) those countries lifting C19 restrictions who now treat C19 like a bad flu and/or use Ivermectin?

3) stories around early successful treatments such as Ivermectin which is being used in 37 countries around the world? E.g. Peru, El Salvador

4) Worldwide protests regarding vaccine mandates and passports;

5) Complete totalitarian lockdown of Australia where police are shooting protesters with rubber bullets here—it looks like a warzone there… **but we hear crickets from CBC?**

On numerous occasions, I have provided evidence that CBC is not meeting their journalistic requirement to deliver balanced, fair and comprehensive reporting regarding the most substantive story of our generation. I have not heard from Mr. Fenlon, so I'm asking Mr. Nagler to contact me directly this morning regarding how our national broadcaster, sadly and concerningly, is letting Canadians down despite being funded, in large part, by taxpayer money.

Mr. Nagler, I can be reached at either number listed below. I look forward to hearing from you.

Sincerely,

Karen Rucas, B.Sc.O.T. Reg (Ont)

Occupational Therapist with training & expertise in life care planning

Life Care Planning Consultant

Cellular: 416-918-0261

Home office: 647-343-2803

--
You received this message because you are subscribed to the Google Groups "Newsgroup" group.
To unsubscribe from this group and stop receiving emails from it, send an email to newsgroup-grp+unsubscribe@cbc.ca.
To view this discussion on the web visit

From:	CBC Ombud <ombud@cbc.ca>	**Livelink ID:**	
To:	Newsgroup <newsgroup-grp@cbc.ca>	**Sent Date:**	2022-4-4 10:03 EDT
CC:		**Received Date:**	2022-4-4 10:03 EDT
Subject:	Fwd: CBC biased reporting on Ivermectin		
Attachments:	Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked..eml		644870
	Scientific review of the study.eml		23602

fyi

Jack Nagler
CBC Ombudsman
ombud@cbc.ca
www.cbc.ca/ombudsman

s.16(2)(c)

CBC Radio-Canada

On my website: Subscribe to reviews

-------- Forwarded message ---------
From: **Karen Rucas** <krahome@rogers.com>
Date: Sat, Apr 2, 2022 at 11:11 AM
Subject: CBC biased reporting on Ivermectin
To: Don Spandier <don.spandier@cbc.ca>
Cc: <ombud@cbc.ca>, BRODIE FENLON <brodie.fenlon@cbc.ca>

Hi Don

One more scientist weighs in on the TOGETHER study you shared with me entitled: *Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked.*

> "I heard from a Canadian generic drug company that it withdrew from the trial because they thought that it was "designed to fail." I heard that the initial planned dosage of ivermectin was even lower than what was used until they received substantial criticism. Certainly, three days is too short, especially when FLCCC recommends five days or until symptoms resolve. Also, they conducted the trial in an area with widespread ivermectin use without prescription. You can be sure that the "controls" were using ivermectin."
>
> "Interestingly, the TOGETHER trial also tested fluvoxamine and found that it was statistically superior to placebo. I doubt that this was the outcome they planned for. Perhaps the reason that fluvoxamine worked was because its background use was low, especially in comparison with ivermectin. It's all another example of destroying science in the name of profit as stated in the Brit Med J- The illusion of evidence based medicine | The BMJ."

Don, providing a critical analysis of this study is called "balanced journalism" but will CBC allow for these other scientists to speak out? I am still waiting to hear back from Brodie Fenlon as to how CBC intends to remediate itself with respect to their initial falsehoods around Ivermectin. Perhaps this would be a good place to start.

Sincerely yours,

Karen Rucas, B.Sc.O.T. Reg (Ont)
Occupational Therapist with training & expertise in life care planning
Life Care Planning Consultant
President/Jarvis Mansions, Toronto
V.President/SQ2, Toronto
Cellular: 416-918-0261
Home office: 647-343-2803

Those who would give up essential liberty, to purchase a little temporary safety, deserve neither liberty nor safety.
Benjamin Franklin (1706-1790)

As a disclaimer, I am neither a physician, a virologist, a molecular biologist or an immunologist, but rather a health care professional who is interested in saving Canadian lives.

Subject: Scientific review of the study
From: "Karen Rucas" <krahome@rogers.com>
Date: 3/31/2022, 4:02 PM
To: "Don Spandier" <don.spandier@cbc.ca>

Hi Don
I had some feedback about that study from world renown scientists/researchers:

First, the way Ivermectin works is in concert with Zinc. There was no zinc given to the trial subjects. As well, the dose of IVM was given after 7 days of COVID-19—TOO LATE in an early outpatient protocol. The PCR data gave no cycle threshold (CT) values which is a key Covid-19 determination factor.

“There are a lot of issues with this ‘trial’ and bit by bit they add up to non-significant differences that inept media translate to ‘high quality study shows no benefit’.”

“…I see that it was performed in Brazil. Isn't the fact that it was done in Brazil a known trick for making ivermectin look bad? I.e., Brazil offers ivermectin as an over-the-counter drug and many residents use it. So, the 'trick' is that the test group gets a known amount of ivermectin and the control group gets an undefined amount of ivermectin. This means the comparison is between ivermectin and ivermectin. I would also take a look at the dosing regimen. In some previous studies another trick was to use a sub-optimal treatment strategy. Just a couple of things to look for in your deep-dive.”

“They have released to media before peer review, which is typical of pharma funded trials. We should express our concerns re Gates funding conflicts of interest, ivm confounding in the placebo group and data release before peer review.”

“The Together Trial was designed to fail. In short, the regulatory authorities should never have accepted this study to go ahead.”

From the paper about this trial: "Clinicians provided consultation on the management of symptoms and provided antipyretic agents; clinicians recommended antibiotic agents only if they suspected bacterial pneumonia." No further mention of administered antibiotics to the two arms in the study. Meanwhile, according to CDC, 50% of the 1M "covid" deaths in USA had comorbidity of non-covid pneumonia. AND ivermectin is an established effective remedy for bacterial pneumonia.

Don, if CBC would like to do a fair and balanced report on Ivermectin, I would be happy to introduce you to all of these Canadian and UK researchers.

Sincerely,

Karen Rucas, B.Sc.O.T. Reg (Ont)
Occupational Therapist with training & expertise in life care planning
Life Care Planning Consultant
Cellular: 416-918-0261
Home office: 647-343-2803

Subject: RE: Breaking News: Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked.
From: "Karen Rucas" <krahome@rogers.com>
Date: 3/31/2022, 9:35 AM
To: "'Don Spandier'" <don.spandier@cbc.ca>

Don, you are so very kind to send me this article, so let's dig in.

Go to pages 48-49 of these study disclosures and you'll find a connection of at least one of the authors with the Bill & Melinda Gates Foundation and all the BIG PHARMA companies including Pfizer. Have our medical journals been hijacked by Big Pharma and Bill Gates? You betcha. In fact, Bill Gates influences vaccine policy as he is the second largest contributor to the WHO and he openly acknowledges "a 20X return" on his vaccine investment.

Here's just one example of a fraudulent study. You might recall early on in the pandemic that hydroxychloroquine was discussed as an early treatment for COVID-19. A Lancet study was done to purposely discredit HCQ and then it was retracted. Many of those authors distanced themselves from this study because it was fraudulent. So you must ask *cui bono*?

Why was the "scientific" community so focussed on discrediting HCQ and IVM? Here's why:

1) If there is a treatment for C19, then by law the novel mRNA vaccines would not qualify for EUA and the companies producing them would not be allowed to skip certain portions of the trial and combine others. (*Don, take a moment this weekend and watch this video prepared by Canadian scientist/researcher Deanna McLeod. In her regular job, she advises on the safety and efficacy of medical equipment in Canada)*. Thus, Pfizer, Moderna and their shareholders would lose billions in potential sales.

2) Both HCQ and IVM are off-patent drugs so none of the big drug companies can make money off them. I spoke to the Therapeutic Directorate of Health Canada and he stated that Merck would NOT endorse their own drug—Ivermectin—as an anti-viral, anti-inflammatory in the early treatment of COVID-19. Without Merck's endorsement, Health Canada could not recommend it. (I was shocked that this is how it works!) Soooo why didn't Merck endorse IVM?

    a. Because IVM is off-patent;
    b. Because they were developing a brand new drug to treat C19, molnupiravir; and
    c. Because Merck had partnered J&J to produce their vaccine.

Thirty-seven countries around the world are using IVM as first line defense, but our media is not covering this. Why? Perhaps because MSM's funding comes from companies like Pfizer—take a moment to look at this compilation. I don't see MSM biting the hand that feeds them.

NEXT: Let's examine the charitable foundations which funded this study—who is behind Rainwater Charitable Foundation and Fast Grants?

- Peter Theil funds Fast Grants. He is also a co-founder of PayPal and invests heavily in FaceBook, both of whom are censoring any dissenting viewpoints regarding the COVID-19 early treatments (e.g. IVM and HCQ) and the mRNA vaccine program. I believe that Mark Zuckerberg and his wife's foundation (The Chan Zuckerberg Initiative) are also involved in COVID-19 vaccines and treatments.
- Rainwater site supports "the use of mRNA technology to create effective COVID-19 vaccines" and has identified "vaccine hesitancy" in their work during the pandemic.

Consequently, the next step is to review the methodology and raw data arising from this study. Once I find out more, I'll let you know. For now, I'm somewhat skeptical of this study based on the above-captioned information. Let me know your thoughts.

Sincerely,

Karen Rucas, B.Sc.O.T. Reg (Ont)
Occupational Therapist with training & expertise in life care planning
Life Care Planning Consultant
Cellular: 416-918-0261
Home office: 647-343-2803

From: Don Spandier [mailto:don.spandier@cbc.ca]
Sent: March-30-22 5:52 PM
To: Karen Rucas
Subject: Fwd: Breaking News: Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked.

Thought you'd be interested

---------- Forwarded message ---------
From: **The New York Times** <nytdirect@nytimes.com>
Date: Wed, Mar 30, 2022 at 5:03 PM
Subject: Breaking News: Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked.

To: <don.spandier@cbc.ca>

View in browser | nytimes.com

BREAKING NEWS

Ivermectin failed as a Covid treatment, a large clinical trial found. The drug surged in popularity despite no strong evidence that it worked.

Wednesday, March 30, 2022 5:02 PM EST

The study, which compared more than 1,300 people infected with the coronavirus in Brazil who received either ivermectin or a placebo, effectively ruled out the drug as a treatment for Covid, the study's authors said.

Read the latest

ADVERTISEMENT

Powered by LiveIntent AdChoices

You received this email because you signed up for NYTimes.com's Breaking News Alerts. To stop receiving these emails, unsubscribe or manage your email preferences.

Subscribe to the Times Get the NYT app

Change Your Email Privacy Policy Contact Advertise California Notice

The New York Times Company, 620 Eighth Avenue, New York, NY 10018

--

Don Spandier (he, him)
Executive Producer,

CBC News.

Attachments:

Study disclosures of conflicts of interest, 2022.pdf 416 KB

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): David
2. Surname (Last Name): Boulware
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Boulware has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Eduardo Diniz
2. Surname (Last Name): Callegari
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Callegari has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Ana Paula Figueiredo
2. Surname (Last Name): de Almeida
3. Date: 02-November-2022

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. de Almeida has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Vitoria Helena
2. Surname (Last Name): de Souza Campos
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. de Souza Campos has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Castilho Vitor Quirino
2. Surname (Last Name): dos Santos
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title
Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it)
21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. dos Santos has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Thiago Santiago
2. Surname (Last Name): Ferreira
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No



ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ferreira has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Jamie
2. Surname (Last Name): Forrest
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Forrest has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Gordon
2. Surname (Last Name): Guyatt
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Guyatt has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Ofir
2. Surname (Last Name): Harari
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Harari has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Paula
2. Surname (Last Name): McKay
3. Date: 24-February-2022

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Craig R Rayner

5. Manuscript Title
Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it)
21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Rainwater Charitable Foundation	☑	☐	☐	☐	Platform Sciences has received financial support from the Rainwater Charitable Foundation to provide scientific support to the Together trial.
Fast Grants	☑	☐	☐	☐	Platform Sciences has received financial support from Fast Grants to provide scientific support to the Together trial.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. McKay reports grants from Rainwater Charitable Foundation, grants from Fast Grants, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Alina Cruz
2. Surname (Last Name): Milagres
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Milagres has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Edward
2. Surname (Last Name): Mills
3. Date: 24-February-2022

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Craig R Rayner

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Bill & Melinda Gates Foundation	☑	☐	☐	☐	Edward Mills is an employee of Cytel. Cytel has received financial support from the Gates foundation to provide scientific support to various COVID projects, but has not funded the TOGETHER trial.
Rainwater Charitable Foundation	☑	☐	☐	☐	Platform Life Sciences has received financial support from the Rainwater Charitable Foundation to provide scientific support to the Together trial.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Fast Grants	☑	☐	☐	☐	Platform Life Sciences has received financial support from Fast Grants to provide scientific support to the Together trial.	

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Mills reports grants from grants from Rainwater Charitable Foundation, grants from Fast Grants, outside the submitted work; .



INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Adhemar Dias de Figueiredo
2. Surname (Last Name): Neto
3. Date: 02-November-2022

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Neto has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Ana Maria Ribeiro
2. Surname (Last Name): Nogueira
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Nogueira has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Rosemary
2. Surname (Last Name): Oliveira
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No



ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Oliveira has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Craig
2. Surname (Last Name): Rayner
3. Date: 24-February-2022

4. Are you the corresponding author? ☑ Yes ☐ No

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): ID 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Bill & Melinda Gates Foundation	☑	☐	☐	☐	Certara has received financial support from the Gates foundation to provide scientific input into various COVID related initiatives.
Australian Government	☑	☐	☐	☐	Certara has received financial support from the Australian government to provide advice on putative therapeutics for COVID. Financial support is not related to Ivermectin or the Together study.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Medicines Development for Global Health	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Novaquest	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Regeneron	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Merck	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Astrazeneca	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Pfizer	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Daichi Sankyo	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.
Commonwealth Science and Research Organization	☑	☐	☐	☐	Certara has received financial support. Not related to ivermectin or Together study.

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rayner reports grants from Bill & Melinda Gates Foundation, grants from Australian Government , grants from Biotechnology and Pharmaceutical companies (various), outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Gilmar
2. Surname (Last Name): Reis
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Card Research	☐	☑	☐	☐	Consulting fees	

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Reis reports personal fees from Card Research, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Luciene Barra
2. Surname (Last Name): Ribeiro
3. Date: 02-November-2022

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ribeiro has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Hinda
2. Surname (Last Name): Ruton
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ruton has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Leonardo Cansado Monteiro
2. Surname (Last Name): Savassi
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☐ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Savassi has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Daniela Carla Medeiros
2. Surname (Last Name): Silva
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Silva has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Eduardo Augusto dos Anjos Moreira
2. Surname (Last Name): Silva
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Silva has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Maria Izabel Campos
2. Surname (Last Name): Simplicio
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Simplicio has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Sheila
2. Surname (Last Name): Sprague
3. Date: 24-February-2022

4. Are you the corresponding author? ☐ Yes ☑ No
Corresponding Author's Name: Craig R Rayner

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☑ Yes ☐ No

If yes, please fill out the appropriate information below.

Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Rainwater Charitable Foundation	☑	☐	☐	☐	Platform Sciences has received financial support from the Rainwater Charitable Foundation to provide scientific support to the Together trial.
Fast Grants	☑	☐	☐	☐	Platform Sciences has received financial support from Fast Grants to provide scientific support to the Together trial.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Sprague reports grants from Rainwater Charitable Foundation, grants from Fast Grants, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.
Grant: A grant from an entity, generally [but not always] paid to your organization
Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations
Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.
Other: Anything not covered under the previous three boxes
Pending: The patent has been filed but not issued
Issued: The patent has been issued by the agency
Licensed: The patent has been licensed to an entity, whether earning royalties or not
Royalties: Funds are coming in to you or your institution due to your patent

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name): Lehana
2. Surname (Last Name): Thabane
3. Date: 02-November-2021

4. Are you the corresponding author? ☐ Yes ☑ No

Corresponding Author's Name: Edward Mills

5. Manuscript Title: Effect of Early Treatment with Ivermectin among Patients with COVID-19

6. Manuscript Identifying Number (if you know it): 21-15869

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? ☐ Yes ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☐ Yes ☑ No

ICMJE INTERNATIONAL COMMITTEE of MEDICAL JOURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ Yes, the following relationships/conditions/circumstances are present (explain below):

☑ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Thabane has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.